[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 226
1. Agarwal B, Krishna NB, Labundy JL, Safdar R, Akduman EI: EUS and/or EUS-guided FNA in patients with CT and/or magnetic resonance imaging findings of enlarged pancreatic head or dilated pancreatic duct with or without a dilated common bile duct. Gastrointest Endosc; 2008 Aug;68(2):237-42; quiz 334, 335
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Incidental findings of an enlarged head of pancreas (HOP) or dilated pancreatic duct (PD) with or without a dilated common bile duct (CBD) on CT or magnetic resonance imaging (MRI), in patients without obstructive jaundice, raise suspicion for a pancreatic neoplasm, but their clinical significance has not been established.
  • OBJECTIVE: To determine the prevalence of pancreatic neoplasm in this patient group.
  • The final diagnosis was based on definitive cytology, surgical pathology, and clinical follow-up.
  • (1) The prevalence of pancreatic neoplasms and (2) performance characteristics of EUS-FNA for identifying malignant neoplasm, in this patient group.
  • RESULTS: In 110 study patients, the final diagnosis included adenocarcinoma (n = 7), pancreatic intraepithelial neoplasia (n = 1), neuroendocrine tumor (n = 1), tumor metastasis (n = 1), and benign cyst (n = 3).
  • The accuracy of EUS and EUS-FNA for diagnosing pancreatic neoplasm in these patients was 99.1%, with 88.8% sensitivity, 100% specificity, 99% negative predicative value, and 100% positive predictive value.
  • CONCLUSION: A pancreatic neoplasm is seen in a clinically significant number of patients with "enlarged HOP" or "dilated PD with or without a dilated CBD" but without obstructive jaundice.
  • EUS-FNA seems highly accurate for diagnosing pancreatic neoplasm in these patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle / methods. Diagnostic Imaging / methods. Endosonography / methods. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Age Distribution. Aged. Cohort Studies. Common Bile Duct / pathology. Common Bile Duct / ultrasonography. Female. Humans. Immunohistochemistry. Incidence. Magnetic Resonance Imaging / methods. Male. Middle Aged. Pancreatic Ducts / pathology. Pancreatic Ducts / ultrasonography. Pancreatitis / diagnosis. Pancreatitis / epidemiology. Prognosis. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Sex Distribution. Survival Analysis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2010 Jan;42(1):68-72 [20066593.001]
  • (PMID = 18423464.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, Fabre JM, Boulez J, Baulieux J, Peix JL, Gigot JF, Hepatobiliary and Pancreatic Section (HBPS) of the Royal Belgian Society of Surgery, Belgian Group for Endoscopic Surgery (BGES), Club Coelio: Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery; 2005 Jun;137(6):597-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Detailed questionnaires were used, focusing on patients, tumors, operative data, and late outcome.
  • Final diagnoses included benign pancreatic diseases in 111 patients (87%; insulinoma: 22, neuroendocrine neoplasm: 20, mucinous cystadenoma: 26, serous cystadenoma: 21, chronic pancreatitis: 11, others: 11), and 16 patients (13%) had malignant pancreatic diseases (insulinoma: 3, neuroendocrine neoplasm: 5, ductal adenocarcinoma: 4, cystadenocarcinoma: 2, renal metastases: 2).
  • Five patients with presumed benign pancreatic disease had malignancy at final pathology.
  • The median tumor size was 30 mm (range, 5-120 mm); 89% of tumors were located in the left pancreas.
  • During a median follow-up of 15 months (range, 3-47 months), 23% of the patients with pancreatic malignancies had tumor recurrence.
  • Late outcome was satisfactory in all patients with benign diseases.
  • CONCLUSIONS: LPR is feasible and safe in selected patients with presumed benign and distal pancreatic tumors.
  • [MeSH-minor] Follow-Up Studies. Humans. Length of Stay. Neoplasm Recurrence, Local. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962401.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


3. Kuo SC, Gananadha S, Scarlett CJ, Gill A, Smith RC: Sporadic pancreatic polypeptide secreting tumors (PPomas) of the pancreas. World J Surg; 2008 Aug;32(8):1815-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic pancreatic polypeptide secreting tumors (PPomas) of the pancreas.
  • BACKGROUND: Sporadic pancreatic neuroendocrine tumors, which predominantly secrete pancreatic polypeptide (PPoma), are rare and have not been associated with a clinical syndrome.
  • Their diagnosis was established by the presence of an enhancing solitary pancreatic tumor on computed tomography (CT) and elevated fasting pancreatic polypeptide hormone levels.
  • Patient 4 underwent distal pancreatectomy for a pancreatic neck tumor causing ductal obstruction and distal parenchymal atrophy.
  • RESULTS: All cases had benign histological features apart from patient 1 whose tumor demonstrated occasional mitotic activity.
  • These tumors have not recurred after a median of 49 (range, 35-57) months.
  • The protein expression in the tumor tissue was measured by SELDI-TOF MS and was different than the profile of pancreatic adenocarcinoma that was previously demonstrated in our laboratory.
  • CONCLUSION: Resection of sporadic PPomas presenting as a solitary well-defined mass with benign histological features results in good long-term survival.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1980 Jun;50(6):1094-9 [7372788.001]
  • [Cites] Br J Surg. 1989 Mar;76(3):248-9 [2655808.001]
  • [Cites] Scott Med J. 1991 Oct;36(5):143 [1788544.001]
  • [Cites] Am J Pathol. 1976 Dec;85(3):675-84 [998736.001]
  • [Cites] Hepatology. 2006 Sep;44(3):658-66 [16941699.001]
  • [Cites] Arch Surg. 1991 Aug;126(8):935-52 [1677802.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2688-91 [6372983.001]
  • [Cites] Pancreas. 2004 Jul;29(1):83 [15211116.001]
  • [Cites] World J Surg. 2004 Dec;28(12 ):1231-8 [15517477.001]
  • [Cites] Am J Gastroenterol. 2006 Mar;101(3):669-72 [16464230.001]
  • [Cites] ANZ J Surg. 2007 Aug;77(8):648-53 [17635277.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):526-32 [10457310.001]
  • [Cites] Lancet. 1976 Feb 14;1(7955):328-30 [54738.001]
  • [Cites] N Engl J Med. 1986 Jul 31;315(5):287-91 [3014338.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1670-8 [16697731.001]
  • [Cites] Arch Surg. 1984 May;119(5):508-14 [6143548.001]
  • [Cites] Acta Pathol Jpn. 1992 Feb;42(2):115-8 [1561882.001]
  • [Cites] ANZ J Surg. 2001 Aug;71(8):475-82 [11504292.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Nov;28(11):1075-81 [15657529.001]
  • [Cites] Ann Intern Med. 1998 Sep 15;129(6):484-94 [9735087.001]
  • [Cites] Srp Arh Celok Lek. 2003 May-Jun;131(5-6):259-65 [14692135.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):263-81 [2820062.001]
  • [Cites] Am J Surg. 1980 Jan;139(1):61-72 [6243207.001]
  • [Cites] Rev Esp Enferm Dig. 1994 Sep;86(3):694-8 [7986606.001]
  • [Cites] Ann Intern Med. 1988 Jan;108(1):64-5 [2827551.001]
  • [Cites] Spec Top Endocrinol Metab. 1982;4:93-138 [6190239.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1101-4 [6467136.001]
  • [Cites] Langenbecks Arch Chir. 1997;382(3):134-7 [9324611.001]
  • [Cites] Lancet. 1978 Jul 1;2(8079):43-4 [78236.001]
  • [Cites] Am J Med Sci. 1999 Jan;317(1):55-8 [9892273.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1146-51 [7194135.001]
  • [Cites] Cent Afr J Med. 1980 Sep;26(9):195-7 [6258796.001]
  • [Cites] Endocrinology. 1968 Dec;83(6):1323-30 [4880986.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Nov 25;376(3):209-19 [145717.001]
  • [Cites] Lancet. 1978 Dec 16;2(8103):1280-2 [82783.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):129-33 [3000569.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(2-3):153-6 [12794252.001]
  • (PMID = 18521664.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 59763-91-6 / Pancreatic Polypeptide
  • [Number-of-references] 42
  •  go-up   go-down


Advertisement
4. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA, Reeder JE: Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol; 2005 Jun;166(6):1807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.
  • After an initial response in most patients, tumors invariably progress to an androgen-independent state.
  • Using immunohistochemistry, we show that interleukin-8 was expressed by the neuroendocrine tumor cells in human prostate cancer tissue.
  • Expression of the interleukin-8 receptor CXCR1 was negative or low in benign prostatic tissue and was frequently increased in malignant cells of high-grade prostatic intraepithelial neoplasia and prostate cancer; however, CXCR1 was not detected in the neuroendocrine tumor cells, suggesting a paracrine mechanism by which interleukin-8 produced by neuroendocrine tumor cells stimulates androgen-independent proliferation of prostate cancer.
  • Neuroendocrine tumor cells expressed another type of interleukin-8 receptor, CXCR2, suggesting an autocrine mechanism by which interleukin-8 regulates the differentiation or function of the neuroendocrine cells.
  • These results, combined with previous reports that neuroendocrine differentiation is induced by hormonal therapy, suggest that neuroendocrine cells play an important role in promoting androgen-independent growth of prostate cancer through interleukin-8 signaling.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Interleukin-8 / biosynthesis. Prostatic Neoplasms / pathology. Receptors, Interleukin-8A / biosynthesis. Receptors, Interleukin-8B / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1991 Sep 13;253(5025):1280-3 [1891716.001]
  • [Cites] Science. 1991 Sep 13;253(5025):1278-80 [1840701.001]
  • [Cites] Chem Immunol. 1992;51:236-65 [1567543.001]
  • [Cites] Cancer. 1992 Jul 1;70(1 Suppl):254-68 [1350941.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2358-66 [1382099.001]
  • [Cites] Science. 1992 Dec 11;258(5089):1798-801 [1281554.001]
  • [Cites] J Biol Chem. 1993 Jan 15;268(2):1338-42 [8419336.001]
  • [Cites] Brain Res. 1993 Jan 8;600(1):49-55 [8422590.001]
  • [Cites] J Urol. 1993 May;149(5):1209-13 [8097794.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):285-92 [8363581.001]
  • [Cites] FEBS Lett. 1994 Mar 21;341(2-3):187-92 [8137938.001]
  • [Cites] Verh Dtsch Ges Pathol. 1993;77:107-10 [7511265.001]
  • [Cites] Arch Pathol Lab Med. 1994 Jun;118(6):616-8 [8204007.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5474-8 [7522959.001]
  • [Cites] Eur Urol. 1995;27 Suppl 2:45-7 [7750532.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Prostate Suppl. 1996;6:3-8 [8630226.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):910-6 [8826857.001]
  • [Cites] J Immunol. 1997 Mar 15;158(6):2882-90 [9058825.001]
  • [Cites] Curr Biol. 1997 Feb 1;7(2):112-21 [9024623.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):450-9 [9092797.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Eur J Immunol. 1998 Jan;28(1):164-70 [9485196.001]
  • [Cites] Urology. 1998 Apr;51(4):585-9 [9586611.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7379-84 [9636157.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4640-5 [9788616.001]
  • [Cites] Urology. 1999 Jan;53(1):139-47 [9886603.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8316-21 [10075738.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] Prostate. 1999 Oct 1;41(2):78-88 [10477904.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] Prostate. 2000 Mar 1;42(4):274-9 [10679756.001]
  • [Cites] Endocrine. 1999 Oct;11(2):195-202 [10709768.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2104-19 [10815938.001]
  • [Cites] Pathol Res Pract. 2000;196(5):277-84 [10834383.001]
  • [Cites] J Urol. 2000 Oct;164(4):1420-5 [10992426.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2892-8 [11306464.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):313-35 [11544102.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):408-17 [12219783.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9 [12231070.001]
  • [Cites] Trends Pharmacol Sci. 2002 Oct;23(10):459-67 [12368070.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6039-44 [12414626.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 2):S36-40 [14713751.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2197-205 [14767470.001]
  • [Cites] Technol Cancer Res Treat. 2004 Oct;3(5):411 [15453805.001]
  • [Cites] Pathol Res Pract. 1987 Jun;182(3):298-307 [2442732.001]
  • [Cites] Prostate. 1989;14(2):103-15 [2710689.001]
  • [Cites] Pathol Res Pract. 1989 Sep;185(3):373-80 [2813190.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Dec 14;173(2):534-40 [2260966.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):287-96 [1313390.001]
  • (PMID = 15920165.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Interleukin-8A; 0 / Receptors, Interleukin-8B
  • [Other-IDs] NLM/ PMC1602414
  •  go-up   go-down


5. Conlon JM: Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors. Regul Pept; 2010 Nov 30;165(1):5-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
  • Chromogranin A-like immunoreactivity (CgA-LI) has been, and remains, the most widely used diagnostic and prognostic marker for endocrine tumors.
  • However, circulating concentrations of CgA-LI are elevated in several non-neoplastic diseases and in patients receiving acid-suppression therapy which may lead to false positive diagnosis.
  • Additionally, certain endocrine tumors, such as rectal carcinoids, do not express the CgA gene so that there is a need for additional markers to complement CgA measurements.
  • Plasma concentrations of the CgA-derived peptide, pancreastatin, measured with antisera of defined regional specificity, have a prognostic value in patients with metastatic midgut carcinoid tumors receiving somatostatin analog therapy or hepatic artery chemoembolization.
  • Other CgA-derived peptides with potential as tumor markers are vasostatin-1, WE-14, catestatin, GE-25, and EL-35 but their value has yet to be fully assessed.
  • Circulating concentrations of chromogranin B-like immunoreactivity (CgB-LI) are not elevated in non-neoplastic diseases and measurements of CCB, the COOH-terminal fragment of CgB, may be useful as a biochemical marker for neuroendocrine differentiation in lung tumors.
  • Antisera to the secretogranin II-derived peptide, secretoneurin detects carcinoid tumors of the appendix with greater frequency than antisera to CgA and are of value in identifying therapy-resistant carcinoma of the prostate (clinical stage D3).
  • Measurement of concentrations of a second secretogranin II-derived peptide, EM-66 in tumor tissue has been used to differentiate between benign and malignant pheochromocytoma.
  • These examples point to a limited although potentially valuable role for granin-derived peptides as tumor markers.
  • [MeSH-major] Chromogranins / metabolism. Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19931574.001).
  • [ISSN] 1873-1686
  • [Journal-full-title] Regulatory peptides
  • [ISO-abbreviation] Regul. Pept.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranin B; 0 / Chromogranins; 0 / Secretogranin II
  •  go-up   go-down


6. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg; 2005 Sep;80(3):1028-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies have suggested that BMP-2 may enhance tumor growth.
  • The present study examined which BMP family members are expressed in non-small cell lung carcinomas (NSCLC).
  • Samples included metastatic NSCLC, benign lung tumors, adenocarcinoma, squamous cell carcinoma, bronchioloalveolar, and neuroendocrine carcinomas.
  • The BMP-2 was over-expressed in all subtypes of NSCLC, including neuroendocrine carcinomas.
  • The BMP-2 expression was similar between squamous cell carcinomas and adenocarcinomas; however, bronchioloalveolar carcinomas tended to have a lower level of expression.
  • The BMP-2 was not significantly expressed in benign lung tumors.
  • The BMP-2 is overexpressed in the majority of human lung carcinomas independent of cell type.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Bone Morphogenetic Protein 2. Bone Morphogenetic Protein 4. Bone Morphogenetic Protein 6. Bone Morphogenetic Protein 7. Carcinoma, Neuroendocrine / genetics. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Growth Differentiation Factor 5. Humans. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Sep;80(3):1032 [16122480.001]
  • (PMID = 16122479.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91919-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / BMP4 protein, human; 0 / BMP6 protein, human; 0 / BMP7 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / GDF5 protein, human; 0 / Growth Differentiation Factor 5; 0 / Transforming Growth Factor beta
  •  go-up   go-down


7. D'Adda T, Bottarelli L, Azzoni C, Pizzi S, Bongiovanni M, Papotti M, Pelosi G, Maisonneuve P, Antonetti T, Rindi G, Bordi C: Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors. Mod Pathol; 2005 Jun;18(6):795-805
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors.
  • Association of X chromosome allelic losses with tumor malignancy has been identified in foregut but not in midgut endocrine neoplasms.
  • The aim of this study was to investigate the association of deletions on X chromosome with malignancy in lung neuroendocrine tumors, another family of foregut neoplasms comprising four categories with increased malignancy: typical and atypical carcinoids, large cell neuroendocrine and small cell lung carcinomas.
  • To evaluate loss of heterozygosity, DNA extracted from nine typical carcinoids, 17 atypical carcinoids, six large cell neuroendocrine carcinomas and five small cell lung carcinomas was PCR-amplified for 18 microsatellite markers spanning the whole X chromosome.
  • X chromosome losses were absent in typical carcinoids, whereas they were found in nine out of 17 atypical carcinoids and in five out of six large cell neuroendocrine carcinomas (involving 28 and 70% of informative loci, respectively).
  • On the contrary, deletions on X chromosome were an extremely rare event in small cell lung carcinomas.
  • In atypical carcinoids, the presence of losses was associated with larger tumor size, higher pT status and advanced stage.
  • In conclusion, X chromosome allelic losses, absent in benign 'typical' carcinoids, progressively increased in frequency from intermediate-grade 'atypical' carcinoids to high-grade large cell neuroendocrine carcinomas.
  • These results extend the association of deletions on X chromosome with malignancy, already demonstrated in other foregut endocrine neoplasms, to lung neuroendocrine tumors.
  • The absence of X chromosome allelic losses in small cell lung carcinomas underlines a striking difference from large cell neuroendocrine carcinomas, possibly linked to different pathogenetic mechanisms of these two highly aggressive neuroendocrine lung tumors.
  • [MeSH-major] Chromosomes, Human, X / genetics. Loss of Heterozygosity. Lung Neoplasms / pathology. Neuroendocrine Tumors / pathology
  • [MeSH-minor] Adult. Aged. Carcinoid Tumor / genetics. Carcinoid Tumor / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / pathology. Female. Humans. Microsatellite Repeats. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15578070.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Sugiyama T, Kouyama R, Tani Y, Izumiyama H, Akashi T, Kishimoto S, Arii S, Hirata Y: Giant malignant insulinoma which developed from a non-functioning pancreatic tumor over a long period of time. Intern Med; 2010;49(15):1573-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant malignant insulinoma which developed from a non-functioning pancreatic tumor over a long period of time.
  • Insulinomas are the most common hormone-producing pancreatic neuroendocrine tumors (NETs), which are usually benign, solitary and small.
  • We describe herein a patient with a giant insulinoma (>10 cm in diameter) with concomitant thyroid tumor as detected by Somatostatin receptor scintigraphy (SRS).
  • A 50-year-old man presented hypoglycemic symptoms 20 years after the first detection of a pancreatic tumor, which was ameliorated by administration of a somatostatin analogue, octreotide.
  • SRS showed abnormal uptake by the insulinoma as well as by the thyroid tumor.
  • RT-PCR and immunohistochemical study revealed abundant expression of somatostatin receptor (SSTR)-1, -2, and -5 in his insulinoma and SSTR-1 and -2 in his thyroid follicular neoplasm.
  • This is a rare case of a slow-growing pancreatic well-differentiated neuroendocrine carcinoma over a long period of time to become a symptomatic giant insulinoma.
  • Furthermore, SRS proves to be a useful tool for localization of insulinoma as well as concomitant thyroid neoplasm with predominant expression of SSTRs.
  • [MeSH-major] Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686293.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


9. Ammori BJ, El-Dhuwaib Y, Ballester P, Augustine T: Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas. Hepatogastroenterology; 2005 Mar-Apr;52(62):620-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas.
  • Although neuroendocrine tumors of the pancreas are traditionally managed by laparotomy, these rare neoplasms may be amenable to laparoscopic surgical resection.
  • Two female patients aged 63 and 69 years presented with clinical and biochemical features of an insulinoma and a vasoactive intestinal peptide secreting tumor (VIPoma), and were found on cross-sectional imaging to have 1.2-cm and 4.5-cm solitary tumors in the tail of the pancreas.
  • Histology revealed a benign insulinoma and a malignant VIPoma with lymph node metastases respectively.
  • Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas may be accomplished safely, with preservation of the spleen and splenic vessels in benign disease, and with benefits to the patients in terms of postoperative recovery.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816491.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Klöppel G: Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab; 2007 Mar;21(1):15-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour biology and histopathology of neuroendocrine tumours.
  • The tumours of the disseminated/diffuse neuroendocrine cell system are a group of neoplasms sharing uniformly appearing cells which differ from each other in their biology, prognosis and genetics.
  • In the lung they are called carcinoid and small/large-cell neuroendocrine carcinomas.
  • In the gastroenteropancreatic compartment they are classified as well-differentiated neuroendocrine tumours or carcinomas and poorly differentiated neuroendocrine carcinomas.
  • Their clinical behaviour--ranging from benign and low-grade to high-grade malignancy--can be predicted on the basis of clinicopathological criteria.
  • [MeSH-major] Neuroendocrine Tumors / pathology
  • [MeSH-minor] Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma / classification. Carcinoma / diagnosis. Carcinoma / genetics. Carcinoma / pathology. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / genetics. Gastrointestinal Neoplasms / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neurosecretory Systems / cytology. Prognosis. Respiratory Tract Neoplasms / classification. Respiratory Tract Neoplasms / diagnosis. Respiratory Tract Neoplasms / genetics. Respiratory Tract Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382263.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


11. Goh BK, Ooi LL, Kumarasinghe MP, Tan YM, Cheow PC, Chow PK, Chung YF, Wong WK: Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology; 2006;6(6):520-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm.
  • BACKGROUND/AIMS: The occurrence of concomitant pancreatic endocrine neoplasm (PEN) and intraductal papillary neoplasm (IPMN) of the pancreas has rarely been reported.
  • Seven of the PENs were classified as benign, 2 were potentially malignant, and 1 was frankly malignant with lymph node involvement.
  • Five of these neoplasms were benign, 2 were borderline and 3 were malignant (1 carcinoma in situ).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Chromogranins / metabolism. Female. Humans. Male. Middle Aged. Synaptophysin / metabolism. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel and IAP.
  • (PMID = 17124434.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


12. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V, Pederzoli P: Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol; 2010 Jun;17(6):1621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors.
  • BACKGROUND: Parenchyma-preserving resections (PPRs), including enucleation and middle pancreatectomy (MP), are accepted procedures for insulinomas, but their role in the treatment of nonfunctioning pancreatic endocrine tumors (NF-PETs) is debated.
  • Median size of the tumors was 13.5 mm with no preoperative suspicion of malignancy in all patients.
  • At pathology, there were 34 (68%) benign lesions, 13 (26%) neoplasms of uncertain behavior, and 3 (6%) well-differentiated carcinomas.
  • Forty-one patients (82%) had tumors < or =2 cm in size.
  • Overall, four patients (8%) experienced tumor recurrence after a mean of 68 months.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neuroendocrine Tumors / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162460.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Semaan MT, Megerian CA: Current assessment and management of glomus tumors. Curr Opin Otolaryngol Head Neck Surg; 2008 Oct;16(5):420-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current assessment and management of glomus tumors.
  • PURPOSE OF REVIEW: To provide an overview on the recent advances in the diagnosis and treatment of glomus tumors (paragangliomas).
  • RECENT FINDINGS: The review focuses on the genetics of paragangliomas and discusses the role of newer therapeutic modalities in the management of jugulotympanic paragangliomas.
  • SUMMARY: Recent advances in the field of genetics allowed the identification of three main loci involved in hereditary paragangliomas.
  • The management of glomus tumors continues to be a challenging task.
  • [MeSH-major] Diagnostic Imaging / methods. Glomus Tumor / diagnosis. Glomus Tumor / surgery. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Angiography / methods. Female. Glomus Jugulare Tumor / diagnosis. Glomus Jugulare Tumor / epidemiology. Glomus Jugulare Tumor / surgery. Humans. Incidence. Magnetic Resonance Imaging / methods. Male. Neoplasm Staging. Paraganglioma / diagnosis. Paraganglioma / epidemiology. Paraganglioma / surgery. Prognosis. Radiographic Image Enhancement. Radiosurgery / methods. Risk Assessment. Survival Rate. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797283.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


14. Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y: Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate; 2006 Sep 15;66(13):1399-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical characterization of neuroendocrine cells in prostate cancer.
  • BACKGROUND: Neuroendocrine (NE) cells increase in high grade/stage prostate cancer (PC) and may contribute to androgen-independent cancer.
  • METHODS: PC tissue was stained immunohistochemically for luminal secretory cell-associated cytokeratin, basal cell markers, ki-67, androgen receptor (AR), PSA, prostate acid phosphatase (PAP), and alpha-methylacyl coenzyme A racemase (AMACR).
  • RESULTS: The NE cells are positive for AE1/AE3, Cam 5.2, and negative for basal cell markers.
  • The benign NE cells are negative for AMACR while the malignant NE cells are positive for AMACR.
  • They are post-mitotic cells but are malignant and part of the tumor.
  • [MeSH-major] Neuroendocrine Tumors / metabolism. Neuroendocrine Tumors / pathology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology
  • [MeSH-minor] Acid Phosphatase / genetics. Acid Phosphatase / metabolism. Androgen Antagonists / pharmacology. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratins / genetics. Keratins / metabolism. Ki-67 Antigen / genetics. Ki-67 Antigen / metabolism. Male. Phenotype. Prostate-Specific Antigen / genetics. Prostate-Specific Antigen / metabolism. Racemases and Epimerases / genetics. Racemases and Epimerases / metabolism. Receptors, Androgen / genetics. Receptors, Androgen / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865726.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Ki-67 Antigen; 0 / Receptors, Androgen; 68238-35-7 / Keratins; EC 3.1.3.2 / Acid Phosphatase; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


15. Fernández-Cruz L, Cosa R, Blanco L, Levi S, López-Boado MA, Navarro S: Curative laparoscopic resection for pancreatic neoplasms: a critical analysis from a single institution. J Gastrointest Surg; 2007 Dec;11(12):1607-21; discussion 1621-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic pancreatic surgery (LPS) has seen significant development but much of the knowledge refers to small and benign pancreatic tumors.
  • This study aims to evaluate the feasibility, safety, and long-term outcome of the laparoscopic approach in patients with benign, premalignant, and overt malignant lesions of the pancreas.
  • The 103 patients were divided based on preoperative diagnosis: group I, inflammatory tumors for chronic pancreatitis (eight patients); group II, cystic pancreatic neoplasms (29 patients); group III, intraductal papillary mucinous neoplasms (10 patients); group IV, neuroendocrine pancreatic tumors (NETs) (43 patients); and group V ductal adenocarcinoma (13 patients).
  • The median tumor size was 5.3 cm.
  • Long-term outcomes were analysed by tumor recurrence and patient survival.
  • R(0) resection was achieved in 90% of ductal adenocarcinoma and 100% for other malignant tumors.
  • This series demonstrates that LPS is feasible and safe in benign-appearing and malignant lesions of the pancreas.
  • [MeSH-minor] Adult. Feasibility Studies. Female. Humans. Length of Stay. Male. Middle Aged. Neuroendocrine Tumors / surgery. Pancreatectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):896-903 [9637553.001]
  • [Cites] Langenbecks Arch Surg. 2005 Apr;390(2):134-40 [15609056.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] HPB (Oxford). 2006;8(1):49-56 [18333239.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):402-6 [14735345.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10(10):1338-45; discussion 1345-6 [17175452.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):103-8 [17008952.001]
  • [Cites] World J Surg. 2004 Dec;28(12 ):1239-47 [15517485.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1358-61 [11984672.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):501-9; discussion 509-11 [10522720.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Surgery. 1996 Nov;120(5):885-90 [8909526.001]
  • [Cites] Semin Laparosc Surg. 1998 Sep;5(3):168-79 [9787203.001]
  • [Cites] J Gastrointest Surg. 2006 May;10(5):752-60 [16773762.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):946-52; discussion 952 [14675703.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1065-70 [8869304.001]
  • [Cites] Surgery. 2001 May;129(5):537-46 [11331445.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Br J Surg. 2005 May;92(5):539-46 [15852419.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Surgeon. 2005 Oct;3(5):317-24 [16245650.001]
  • [Cites] ANZ J Surg. 2003 Nov;73(11):922-5 [14616571.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):890-7 [14592663.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):407-11 [14752628.001]
  • [Cites] J Trauma. 1991 Mar;31(3):431 [2002537.001]
  • [Cites] Surgery. 2003 May;133(5):521-7 [12773980.001]
  • [Cites] Surg Endosc. 1994 May;8(5):408-10 [7915434.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):381-8 [15749601.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):837-42 [15985241.001]
  • [Cites] Surgery. 2000 Sep;128(3):386-91 [10965308.001]
  • [Cites] J Am Coll Surg. 1999 Mar;188(3):255-60 [10065814.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):149-58 [12170019.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:227s-230s [12487288.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):95-8 [16368497.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1057-65 [12016486.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):190-6 [12555295.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):205-12 [10674612.001]
  • [Cites] Cancer Treat Rev. 2005 Nov;31(7):507-35 [16257126.001]
  • [Cites] Surg Endosc. 2006 Apr;20 Suppl 2:S446-9 [16557419.001]
  • [Cites] Surgery. 2006 Mar;139(3):288-95 [16546491.001]
  • [Cites] J Gastrointest Surg. 2005 Sep-Oct;9(7):922-7 [16137585.001]
  • [Cites] World J Surg. 2002 Oct;26(10):1297-300 [12205557.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):493-501 [15120376.001]
  • (PMID = 17896167.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lee M, Kalani MY, Cheshier S, Gibbs IC, Adler JR, Chang SD: Radiation therapy and CyberKnife radiosurgery in the management of craniopharyngiomas. Neurosurg Focus; 2008;24(5):E4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Many benign intracranial tumors are amenable to radiotherapy treatment including meningiomas, schwannomas, pituitary tumors, and craniopharyngiomas.
  • The authors discuss the role of radiation therapy in the management of these tumors, and more specifically, the role of CyberKnife SRS.
  • All patients underwent magnetic resonance imaging and visual and neuroendocrine evaluations before and at regular intervals after SRS.
  • A multisession treatment regimen and a nonisocentric treatment plan for each patient were used with a mean marginal dose of 21.6 Gy and a mean maximal dose of 29.9 Gy.
  • Evaluation of patients between 13 and 71 years of age (mean 34.5 years) with a mean follow-up period of 15.4 months revealed no deterioration in visual or neuroendocrine function.
  • Tumor shrinkage was achieved in 7 of these 11 patients, and tumor control in another 3.
  • One patient had cystic enlargement of the residual tumor.
  • CONCLUSIONS: The authors' early experience with the application of CyberKnife SRS to residual or recurrent craniopharyngiomas has been positive; control or shrinkage of the tumor was achieved in 91% of patients, with no visual or neuroendocrine complications.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Optic Nerve Diseases / etiology. Remission Induction. Retrospective Studies. Salvage Therapy. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447743.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


17. Feng N, Zhang WY, Wu XT: Clinicopathological analysis of paraganglioma with literature review. World J Gastroenterol; 2009 Jun 28;15(24):3003-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of paraganglioma with literature review.
  • AIM: To investigate the 152 cases of paragangliomas resected over the past 32 years in West China Hospital clinicopathologically.
  • METHODS: All cases of paragangliomas diagnosed at the Department of Gastrointestinal Surgery and Department of Pathology, West China Hospital, China were reviewed.
  • RESULTS: The neuroendocrine marker vimentin was found to be selectively expressed in the benign tumors, and there were significant differences in the expression of those markers in both benign and malignant tumors.
  • CONCLUSION: Vimentin may be useful in the differential diagnosis between malignant and benign tumors.
  • The difference in the expression of this marker in the tumors could be a clue to the future clinical diagnosis.
  • [MeSH-major] Paraganglioma / diagnosis. Paraganglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. China. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Vimentin / metabolism. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2004 Sep;17(9):1119-28 [15167935.001]
  • [Cites] Med Mol Morphol. 2008 Mar;41(1):59-61 [18470682.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] APMIS. 2004 Sep;112(9):551-9 [15601303.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):13-8 [15608506.001]
  • [Cites] Horm Metab Res. 2005 Jun;37(6):384-90 [16001332.001]
  • [Cites] Eur J Endocrinol. 2008 Feb;158(2):247-53 [18230833.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 May;265(5):557-63 [17987308.001]
  • [Cites] World J Surg. 2008 May;32(5):683-7 [18224469.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1272-84 [18684026.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2008 Nov;36(5):517-9 [18692411.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1427-34 [11903030.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] J Med Genet. 2002 Sep;39(9):617-22 [12205103.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66 [12788870.001]
  • [Cites] Ann Chir. 2003 May;128(4):232-6 [12853019.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7 [12970267.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):479-91 [14764749.001]
  • [Cites] Adv Anat Pathol. 2004 Jul;11(4):175-89 [15220821.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1018:495-504 [15240407.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):85-90 [15264276.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):568-80 [15294882.001]
  • [Cites] Int J Urol. 1999 Mar;6(3):119-24 [10226821.001]
  • (PMID = 19554653.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2702108
  •  go-up   go-down


18. Long KB, Srivastava A, Hirsch MS, Hornick JL: PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol; 2010 May;34(5):723-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
  • PAX (paired box) genes encode a family of transcription factors that regulate organogenesis and cell-lineage specification in multiple organ systems.
  • In the pancreas, PAX proteins play a critical role in islet cell differentiation.
  • However, PAX8 expression has not previously been examined in pancreatic endocrine tumors (PETs).
  • PAX8 expression in other well-differentiated neuroendocrine tumors (WDNETs) was also studied.
  • In total, 190 tumors were evaluated: 156 primary WDNETs (63 PETs, 31 ileal, 5 duodenal, 5 gastric, 19 appendiceal, 13 rectal, and 20 pulmonary carcinoid tumors) and 34 liver metastases (18 PETs and 16 ileal carcinoid tumors).
  • Expression of PAX8 was significantly associated with WHO category 1.1 ("benign" behavior) compared with category 1.2 (uncertain behavior) or 2 (well-differentiated endocrine carcinoma) (positive in 100%, 64%, and 52% of tumors, respectively; P<0.05).
  • PAX8-positive PETs were also significantly smaller and more often clinically functional; PAX8-negative tumors were more frequently associated with liver metastases.
  • PAX8 expression was detected in 0/20 (0%) pulmonary, 1/5 (20%) gastric, 5/5 (100%) duodenal, 0/31 (0%) ileal, 4/19 (21%) appendiceal, and 11/13 (85%) rectal carcinoid tumors.
  • Among the liver metastases, PAX8 was positive in 9/18 (50%) metastatic PETs compared with 0/16 (0%) metastatic ileal carcinoid tumors.
  • In the GI tract, PAX8 is positive in the majority of duodenal and rectal carcinoid tumors, and in a minor subset of appendiceal and gastric carcinoids.
  • PAX8 expression is absent in ileal and pulmonary carcinoid tumors.
  • PAX8 immunostaining may be helpful in determining the primary site for a WDNET metastatic to the liver, as ileal (PAX8 negative) and pancreatic (PAX8 positive) tumors most often present as a metastasis from an occult primary.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoid Tumor / pathology. Carcinoma, Islet Cell / secondary. Gastrointestinal Neoplasms / pathology. Lung Neoplasms / pathology. Paired Box Transcription Factors / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Dec;35(12):1906-8 [22067332.001]
  • (PMID = 20414099.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


19. Cadden IS, Atkinson AB, Johnston BT, Pogue K, Connolly R, McCance D, Ardill JE, Russell CF, McGinty A: Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism. Histopathology; 2007 Dec;51(6):743-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Phaeochromocytomas are rare but potentially life-threatening neuroendocrine tumours of the adrenal medulla or sympathetic nervous system ganglia.
  • There are no histological features which reliably differentiate benign from malignant phaeochromocytomas.
  • METHODS AND RESULTS: COX-2 and Bcl-2 expression were examined immunohistochemically in tissue from 41 sporadic phaeochromocytoma patients followed up for a minimum of 5 years after diagnosis.
  • There was a statistically significant association between COX-2 histoscore (intensity x proportion) and the development of tumour recurrence or metastases (P = 0.006).
  • A significant relationship was observed between coexpression of COX-2 and Bcl-2 in the primary tumour and the presence of recurrent disease (P = 0.034).
  • A highly significant association was observed between (i) tumour-associated expression of these two oncoproteins (P = 0.001) and (ii) COX-2 histoscore and the presence of Bcl-2 expression (P = 0.002).
  • CONCLUSIONS: COX-2 and Bcl-2 may promote phaeochromocytoma malignancy, and these oncoproteins may be valuable surrogate markers of an aggressive tumour phenotype.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / analysis. Cyclooxygenase 2 / biosynthesis. Pheochromocytoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916073.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


20. Havekes B, van der Klaauw AA, Hoftijzer HC, Jansen JC, van der Mey AG, Vriends AH, Smit JW, Romijn JA, Corssmit EP: Reduced quality of life in patients with head-and-neck paragangliomas. Eur J Endocrinol; 2008 Feb;158(2):247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced quality of life in patients with head-and-neck paragangliomas.
  • OBJECTIVE: The objective of this study was to assess the quality of life (QoL) in patients with head-and-neck paragangliomas ('glomus tumors').
  • METHODS: We assessed QoL in 82 patients with head-and-neck paragangliomas using four validated health-related questionnaires: Hospital Anxiety and Depression Scale, Multidimensional Fatigue Index (MFI-20), Short Form-36 (SF-36), and Nottingham Health Profile (NHP).
  • RESULTS: The QoL scores in the paraganglioma patients were significantly reduced in 12 out of the 21 subscales compared with own controls, and in 18 out of the 21 subscales compared with age- and sex-adjusted values derived from the previous studies.
  • In the MFI-20 questionnaire, patients reported more general fatigue, physical fatigue, mental fatigue, and a reduction in activity and motivation.
  • General health perception, pain, and physical functioning were reported to be worse in the paraganglioma patients on the SF-36 scale.
  • CONCLUSION: QoL is considerably reduced in patients with head-and-neck paragangliomas.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18230833.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Yang JY, Yang MQ, Luo Z, Ma Y, Li J, Deng Y, Huang X: A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics; 2008;9 Suppl 1:S23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because more than one marker must be considered to obtain a classification of cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent decision system that can fullfill such an unmet medical need.
  • We have also used immunohistochemistry techniques to measure the gene expression profiles from a number of antigens such as cyclin E, P27KIP1, FHIT, Ki-67, PCNA, Bax, Bcl-2, P53, Fas, FasL and hTERT in several particular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyperplasia (ACH) involved with Cushing's syndrome.
  • We provided statistical evidence that higher expression levels of hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed to benign.
  • We also investigated whether higher expression levels of P27KIP1 and FHIT, etc., are associated with a decreased risk of adrenomedullary tumors.
  • While no significant difference was found between cell-arrest antigens such as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of such antigens in normal adrenal medulla samples and in adrenomedullary tumors.
  • This research has many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.
  • [MeSH-major] Adrenal Cortex Neoplasms / classification. Algorithms. Artificial Intelligence. Biomarkers, Tumor / metabolism. Cushing Syndrome / classification
  • [MeSH-minor] China. Gene Expression Profiling. Humans. Immunohistochemistry. In Situ Hybridization. Logistic Models. Proliferating Cell Nuclear Antigen / metabolism. Reverse Transcriptase Polymerase Chain Reaction


22. Tajima S, Maeda I, Kanemaki Y, Nakajima Y, Tatsunami S, Fukuda M, Takagi M: Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma. Pathol Int; 2010 Jun;60(6):459-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endocrine ductal carcinoma in situ (E-DCIS) is an intraductal carcinoma characterized by endocrine features and expression of neuroendocrine markers.
  • However, the former is an intraductal carcinoma, and the latter is an intraductal benign lesion.
  • However, it is considered that E-DCIS diagnosis is possible by diffuse immunopositivity of CD56 after having been based on histopathology.
  • [MeSH-major] Antigens, CD56 / metabolism. Antigens, CD57 / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Papilloma, Intraductal / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged. Reproducibility of Results. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pathol Int. 2011 Jan;61(1):49-51 [21166944.001]
  • (PMID = 20518901.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Antigens, CD57; 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Schima W, Ba-Ssalamah A, Plank C, Kulinna-Cosentini C, Prokesch R, Tribl B, Sautner T, Niederle B: [Pancreas. Part II: Tumors]. Radiologe; 2006 May;46(5):421-37; quiz 438
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreas. Part II: Tumors].
  • Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head in 60-70% of cases.
  • By the time of diagnosis, approximately 80% of tumors are unresectable.
  • Serous cystadenoma is benign, has a lobulated contour and contains innumerable small cysts of 0.1-2 cm in diameter.
  • Neuroendocrine tumors are mostly hypervascular.
  • Diagnosis of insulinoma is a challenge: they are <2 cm in 90% of cases and mostly hypervascular at CT or MRI.
  • A combination of contrast-enhanced MDCT, MRI, endosonography, and/or somatostatin receptor scintigraphy is used to detect these small tumors.
  • This review summarizes the imaging features of the most common pancreatic tumors and discusses the limitations of CT, MRI and endosonography.
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] Br J Radiol. 1998 Nov;71(851):1208-14 [10434919.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):218-24 [12145600.001]
  • [Cites] Abdom Imaging. 1997 Jul-Aug;22(4):429-33 [9157866.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10 ):753-63 [15545675.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):297-9 [7075134.001]
  • [Cites] Radiologe. 2003 Apr;43(4):293-300 [12721645.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Radiologe. 2003 Apr;43(4):301-5 [12721646.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):231-4 [11246351.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Radiology. 2000 Jul;216(1):163-71 [10887243.001]
  • [Cites] Radiology. 1991 Aug;180(2):337-9 [1906189.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):441-7 [10658722.001]
  • [Cites] Br J Radiol. 2000 Nov;73(875):1165-9 [11144793.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):987-92 [14500214.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Radiology. 1993 Mar;186(3):795-8 [8430190.001]
  • [Cites] Wien Klin Wochenschr. 2004 Jun 30;116(11-12):373-8 [15291289.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Radiology. 1988 Feb;166(2):413-6 [3336716.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):494-504 [7960219.001]
  • [Cites] Br J Radiol. 1998 May;71(845):492-6 [9691893.001]
  • [Cites] Eur J Radiol. 2001 May;38(2):78-93 [11335090.001]
  • [Cites] Eur Radiol. 2001;11(10 ):1939-51 [11702126.001]
  • [Cites] Eur J Radiol. 2001 May;38(2):113-9 [11335093.001]
  • [Cites] Radiology. 2002 Dec;225(3):759-65 [12461258.001]
  • [Cites] Radiographics. 1999 Nov-Dec;19(6):1447-63 [10555668.001]
  • [Cites] Radiology. 1991 Jan;178(1):95-9 [1984331.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):677-84 [10701608.001]
  • [Cites] Clin Radiol. 1994 May;49(5):295-303 [8013189.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):2998-3008 [12439582.001]
  • [Cites] Radiology. 2000 Dec;217(3):757-64 [11110940.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):419-25 [14736675.001]
  • [Cites] Radiology. 1992 Apr;183(1):87-95 [1312736.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):230-3 [2154172.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jun;172(6):1555-9 [10350288.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:1-3 [10436773.001]
  • [Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]
  • [Cites] J Magn Reson Imaging. 2000 Aug;12 (2):261-8 [10931589.001]
  • [Cites] Wien Klin Wochenschr. 2003;115 Suppl 2:10-8 [15518140.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):323-37; discussion 337-40 [11259696.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Radiologe. 1999 Jul;39(7):568-77 [10472085.001]
  • [Cites] World J Surg. 1999 Sep;23(9):913-9 [10449820.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] J Comput Assist Tomogr. 1996 Mar-Apr;20(2):249-53 [8606232.001]
  • [Cites] Rofo. 2004 Nov;176(11):1624-33 [15497081.001]
  • [Cites] J Comput Assist Tomogr. 2002 Jan-Feb;26(1):126-8 [11801915.001]
  • [Cites] J Comput Assist Tomogr. 2002 Sep-Oct;26(5):743-9 [12439309.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Eur Radiol. 2001;11(7):1175-83 [11471608.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • (PMID = 16715226.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 66
  •  go-up   go-down


24. Sigurdardottir JM, Isaksson HJ, Johannsson KB, Jonsson S, Gudbjartsson T: [Histology does not accurately predict the clinical behaviour of bronchopulmonary carcinoids - results from an Icelandic population-based study]. Laeknabladid; 2008 Feb;94(2):125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Bronchopulmonary carcinoids (BPC) are rare tumors of neuroendocrine origin.
  • These tumors are histologically classified into two distinctive forms, typical and the more malignant atypical BPC.
  • Average tumor-diameter was 2.5 cm (range 0.4-5.5), with typical histology in 54 (84%) and atypical in 10 patients (16%).
  • CONCLUSION: BPCs usually behave as benign neoplasms, with excellent long-term survival after surgical removal.
  • Therefore, histology (typical vs. atypical) can not be used with certainty to predict the clinical behaviour of these tumors.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Iceland / epidemiology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Population Surveillance. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310777.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


25. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA: Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol; 2010 Aug;34(8):1147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction of hepatocellular carcinoma (HCC) from metastatic tumor in the liver often presents a diagnostic challenge that carries significant impact on prognostication and therapy.
  • The sensitivities of Arg-1 in well, moderately, and poorly differentiated HCCs are 100%, 96.2%, and 85.7%, respectively, whereas, in comparison, HepPar-1 demonstrated sensitivities of 100%, 83.0%, and 46.4% for well, moderately, and poorly differentiated tumors, respectively.
  • We also examined Arg-1 expression in nonhepatocellular tumors, including many that are potential mimics of HCC (renal cell carcinomas, neuroendocrine tumors, melanomas, gastric adenocarcinomas, and adrenocortical carcinomas) and found that only 2 non-HCC tumors were reactive for Arg-1.
  • Arg-1 represents a sensitive and specific marker of benign and malignant hepatocytes that may ultimately prove to be a useful diagnostic tool in routine surgical pathology practice.
  • [MeSH-major] Arginase / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / enzymology. Hepatocytes / enzymology. Immunohistochemistry. Liver Neoplasms / enzymology
  • [MeSH-minor] Brazil. Cell Differentiation. Humans. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis. United States

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Clin Nutr Metab Care. 1998 Jul;1(4):335-9 [10565370.001]
  • [Cites] J Biomed Biotechnol. 2010;2010:683485 [20029630.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):689-94 [11345832.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):978-88 [12170084.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):361-6 [12645337.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7565-73 [15187136.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):884-92 [15198362.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):514-20 [15221469.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2820S-2825S; discussion 2853S [15465793.001]
  • [Cites] Histochemistry. 1987;87(5):465-70 [3323144.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1050-4 [7692729.001]
  • [Cites] Int J Dev Neurosci. 1994 Jun;12(4):337-42 [7976488.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):686-92 [9237179.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5347-54 [9605134.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):934-8 [9796718.001]
  • [Cites] Histopathology. 1998 Oct;33(4):318-24 [9822920.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2549-56 [15546957.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Acta Cytol. 2006 May-Jun;50(3):257-62 [16780018.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Aug;28(4):181-7 [16927637.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):308-14 [16896894.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1570-5 [17122513.001]
  • [Cites] Arch Pathol Lab Med. 2007 Nov;131(11):1648-54 [17979482.001]
  • [Cites] Lab Invest. 2008 Jan;88(1):78-88 [18026163.001]
  • [Cites] Toxicology. 2008 Mar 20;245(3):194-205 [18291570.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):224-30 [18628091.001]
  • [Cites] Arch Pathol Lab Med. 2008 Nov;132(11):1723-8 [18976006.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 12;377(2):337-40 [18831962.001]
  • [Cites] BMC Dev Biol. 2008;8:107 [19000307.001]
  • [Cites] Int J Oncol. 2009 Mar;34(3):649-56 [19212669.001]
  • [Cites] PLoS Pathog. 2009 Apr;5(4):e1000371 [19360123.001]
  • [Cites] Acta Biochim Pol. 2009;56(3):465-9 [19636440.001]
  • [Cites] J Pathol. 2009 Nov;219(3):365-72 [19718708.001]
  • [Cites] Nitric Oxide. 2009 Nov-Dec;21(3-4):175-83 [19638312.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20661013.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK081417; United States / NIDDK NIH HHS / DK / R01 DK081417-01; United States / NIDDK NIH HHS / DK / R01 DK081417-02
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.3.1 / Arginase
  • [Other-IDs] NLM/ NIHMS316258; NLM/ PMC3160135
  •  go-up   go-down


26. Yamada M, Otsuki Y, Shimizu S, Tanioka F, Ogawa H, Kobayashi H: Cytological study of 20 cases of solid-papillary carcinoma of the breast. Diagn Cytopathol; 2007 Jul;35(7):417-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In each of the cytological specimens, we could find both malignant and benign cytological features; the former were characterized by hypercellularity, highly discohesive clusters, numerous isolated cells, and severe overcrowding cells, while the latter were marked by small and bland nuclei, a low nuclear-cytoplasmic ratio, and inconspicuous nucleoli.
  • Neither abnormal naked nuclei of tumor cell origin nor oval naked nuclei of myoepithelial cell origin were seen.
  • We also reviewed the cytological findings of SPC as well as neuroendocrine carcinomas with intraductal components that had been reported and we concluded that the coexistence of malignant and benign features was the most characteristic cytological feature of SPC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Diseases / pathology. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580353.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Hisaoka M, Takamatsu Y, Hirano Y, Maeda H, Hamada T: Sebaceous carcinoma of the breast: case report and review of the literature. Virchows Arch; 2006 Oct;449(4):484-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sebaceous differentiation has been described in only limited examples of benign and malignant epithelial lesions of the breast.
  • We report a rare case of mammary sebaceous carcinoma to further delineate its morphologic features.
  • Microscopically, the tumor, arising in the right mammary gland of a 63-year-old woman, was composed of well-defined solid sheets or lobules of atypical epithelial cells including many large pale or clear cells with often scalloped nuclei and coarsely vacuolated cytoplasm, in which abundant lipid droplets were identified with oil-red-O staining.
  • Besides, a subset of the tumor cells co-expressed synaptophysin, neurofilament, and PGP9.5, suggesting neuroendocrine differentiation that is a hitherto undescribed phenomenon in the mammary tumors with sebaceous features.
  • This case would expand the morphologic diversity of carcinoma of the breast.
  • [MeSH-minor] Azo Compounds. Biomarkers, Tumor / analysis. Coloring Agents. Female. Fluorescent Antibody Technique, Indirect. Humans. Keratins / analysis. Mammography. Mastectomy, Modified Radical. Middle Aged. Mucin-1 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 1999 Oct;21(5):426-31 [10535570.001]
  • [Cites] Pathology. 1995 Jul;27(3):280-3 [8532397.001]
  • [Cites] Am J Dermatopathol. 2005 Jun;27(3):195-203 [15900121.001]
  • [Cites] Arch Ophthalmol. 1999 Jun;117(6):776-83 [10369589.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):541-2 [10658739.001]
  • [Cites] Pathol Int. 2000 Jan;50(1):63-6 [10692180.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):127-37 [10839613.001]
  • [Cites] Histopathology. 1992 Aug;21(2):181-4 [1324221.001]
  • [Cites] Hum Pathol. 1982 Feb;13(2):113-22 [7076199.001]
  • [Cites] Histopathology. 1993 Feb;22(2):127-33 [7681028.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Oct 7;375(4):345-53 [199989.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1045-53 [3022669.001]
  • [Cites] Virchows Arch. 2001 May;438(5):505-8 [11407480.001]
  • [Cites] Endocr J. 2005 Jun;52(3):317-25 [16006726.001]
  • (PMID = 16944238.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Azo Compounds; 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins; G7S71FND9B / oil red O
  •  go-up   go-down


28. Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P: Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch; 2007 Aug;451 Suppl 1:S9-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.
  • The gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are composed of cells with a neuroendocrine phenotype.
  • Well-differentiated tumors, well-differentiated carcinomas, poorly differentiated carcinomas, functioning tumors (with a hormonal syndrome), and nonfunctioning tumors are identified.
  • To predict their clinical behavior, these neuroendocrine tumors are classified on the basis of their clinicopathological features, including size, local invasion, angioinvasion, proliferative activity, histological differentiation, and metastases, into neoplasms with benign, uncertain, low-grade malignant and high-grade malignant behavior.
  • In addition, a tumor/nodes/metastases classification and a grading system are presented.
  • [MeSH-major] Digestive System Neoplasms / classification. Digestive System Neoplasms / pathology. Neuroendocrine Tumors / classification. Neuroendocrine Tumors / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1984 Dec;8(12):917-24 [6097131.001]
  • [Cites] Surgery. 1986 Jun;99(6):671-8 [2424108.001]
  • [Cites] Am J Surg. 1980 May;139(5):682-90 [6258453.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Am J Surg. 1964 Aug;108:132-41 [14195205.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Surgery. 1992 Apr;111(4):466-71 [1557693.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):517-22 [11914632.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1329-34 [1678681.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Lancet. 1977 Mar 26;1(8013):666-8 [66472.001]
  • [Cites] Medicine (Baltimore). 1949 Dec;28(4):427-47 [15399004.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):605-10 [12734754.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):811-7 [12766586.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):394-8 [16418841.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):185-90 [6258500.001]
  • [Cites] Hum Pathol. 1985 Jul;16(7):746-51 [3891579.001]
  • [Cites] Regul Pept. 1987 Jan;17(1):9-29 [2882565.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1075-82 [9298884.001]
  • [Cites] Gastroenterol Clin North Am. 1989 Dec;18(4):671-93 [2575601.001]
  • [Cites] Endocr Pathol. 1995 Autumn;6(3):229-237 [12114744.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):475-89 [2869609.001]
  • [Cites] Yale J Biol Med. 1996 Jan-Feb;69(1):69-74 [9041691.001]
  • [Cites] Hum Pathol. 1979 May;10(3):350-3 [89070.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1581-7 [17122515.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):51-67 [6258288.001]
  • [Cites] Neuroendocrinology. 2005;81(6):400-4 [16276118.001]
  • [Cites] Gastroenterology. 1968 Dec;55(6):677-86 [4302500.001]
  • [Cites] Br J Surg. 1993 Apr;80(4):502-4 [8495322.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S39-46 [17684763.001]
  • [Cites] Am J Pathol. 1984 Nov;117(2):167-70 [6093542.001]
  • [Cites] Surg Today. 1997;27(2):112-9 [9017986.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):677-82 [222222.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):248-54 [15517368.001]
  • [Cites] N Engl J Med. 1986 Jul 31;315(5):287-91 [3014338.001]
  • [Cites] J Clin Gastroenterol. 2001 Aug;33(2):154-6 [11468445.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1233-9 [15316325.001]
  • [Cites] Ann Surg. 1981 Dec;194(6):692-7 [7030236.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Ann Surg. 1989 Apr;209(4):396-404 [2930285.001]
  • [Cites] Am J Clin Pathol. 1989 Jan;91(1):52-6 [2462784.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1975;365(4):275-88 [46649.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):952-5 [10970700.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2204-10 [11596039.001]
  • [Cites] Mayo Clin Proc. 1974 Jan;49(1):44-51 [4149030.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;405(3):311-23 [2579503.001]
  • [Cites] Scand J Gastroenterol. 1980;15(2):129-35 [6247758.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):588-94 [15832081.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):468-79 [3532971.001]
  • [Cites] Digestion. 1999 Sep-Oct;60(5):428-39 [10473967.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Ann Surg. 1983 May;197(5):594-607 [6847279.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2029-37 [6271390.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):175-80 [8119718.001]
  • [Cites] Mayo Clin Proc. 1990 Nov;65(11):1399-407 [1700240.001]
  • [Cites] Dig Dis Sci. 1991 Jul;36(7):933-42 [2070707.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Dec;17(4):379-88 [10089055.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2540-5 [2655873.001]
  • [Cites] Am J Gastroenterol. 1981 Aug;76(2):125-31 [6272569.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):963-5 [14645360.001]
  • [Cites] J Pediatr Surg. 1985 Dec;20(6):734-6 [3003324.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):560-74 [16699310.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):706-11 [14608896.001]
  • [Cites] Cancer. 1979 Nov;44(5):1853-9 [227580.001]
  • [Cites] Am J Surg. 1985 Jun;149(6):775-9 [2409828.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1531-6 [17122508.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1860-74 [6627205.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1587-95 [15742328.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):25-31 [6691547.001]
  • [Cites] N Engl J Med. 1979 Aug 9;301(6):285-92 [377080.001]
  • [Cites] Gut. 2007 May;56(5):637-44 [17135306.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):43-50 [17270665.001]
  • [Cites] Mol Endocrinol. 1989 Oct;3(10):1589-95 [2691879.001]
  • [Cites] Mayo Clin Proc. 1976 Jul;51(7):417-29 [180358.001]
  • [Cites] J Surg Oncol. 1991 Mar;46(3):174-7 [1849211.001]
  • [Cites] Am J Surg Pathol. 1977 Sep;1(3):207-16 [920868.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):772-8 [3026608.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17(4):481-8 [8103250.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2894-9 [8199985.001]
  • [Cites] Am J Surg Pathol. 1984 Aug;8(8):607-14 [6205601.001]
  • [Cites] Am J Surg. 1979 Jan;137(1):142-8 [215044.001]
  • [Cites] Mayo Clin Proc. 1991 Jul;66(7):711-9 [1677058.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2097-108 [6435852.001]
  • [Cites] Scand J Gastroenterol Suppl. 1979;53:79-91 [290036.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1086-93 [9070484.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Am J Surg. 1983 Jul;146(1):124-32 [6869670.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):263-81 [2820062.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):217-23 [10782879.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):969-75 [15958864.001]
  • [Cites] Dis Colon Rectum. 1972 Sep-Oct;15(5):383-91 [4561188.001]
  • [Cites] Digestion. 1995;56(6):455-62 [8536814.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):8-18 [1531004.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):776-81 [11787850.001]
  • [Cites] Pathol Res Pract. 1992 Aug;188(6):751-6 [1437839.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Gut. 2002 Aug;51(2):184-90 [12117877.001]
  • [Cites] Ann Surg. 1955 Oct;142(4):709-23; discussion, 724-8 [13259432.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Jun;56(6):1236-42 [6132927.001]
  • [Cites] Mayo Clin Proc. 1978 Jan;53(1):19-23 [625140.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] J Clin Pathol. 2001 Nov;54(11):880-2 [11684726.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):223-31 [9665483.001]
  • [Cites] Gastroenterology. 1985 Mar;88(3):798-803 [2981755.001]
  • [Cites] Am J Gastroenterol. 1986 Jan;81(1):33-7 [2867674.001]
  • [Cites] Am J Clin Pathol. 1987 Aug;88(2):153-61 [2887104.001]
  • [Cites] Arch Pathol Lab Med. 1990 Jul;114(7):700-4 [1694655.001]
  • [Cites] Pathol Res Pract. 1988 Apr;183(2):155-68 [2898775.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):9-14 [2294850.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):327-333 [12114794.001]
  • [Cites] Histopathology. 1992 Sep;21(3):215-23 [1356906.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):183-5 [8459042.001]
  • [Cites] World J Gastroenterol. 2006 Sep 14;12(34):5440-6 [17006979.001]
  • [Cites] Am J Surg Pathol. 1986 May;10(5):348-57 [2422964.001]
  • [Cites] Am J Surg. 1980 Jul;140(1):119-25 [6249135.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2264-71 [16258711.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):251-5 [9500228.001]
  • [Cites] Surgery. 1974 Apr;75(4):597-609 [4366135.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1551-8 [14657715.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Med Pediatr Oncol. 2002 Jan;38(1):65-6 [11835243.001]
  • [Cites] N Engl J Med. 1990 Mar 15;322(11):723-7 [1968616.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • [Cites] Gastroenterology. 1993 Apr;104(4):994-1006 [7681798.001]
  • [Cites] Lancet. 1963 Feb 2;1(7275):238-9 [14000847.001]
  • [Cites] Diabetes. 1979 Oct;28(10):925-36 [383556.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2320-2 [8402445.001]
  • [Cites] Br J Surg. 1979 Jun;66(6):373-8 [223712.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):139-48 [9700573.001]
  • [Cites] Postgrad Med J. 1995 Aug;71(838):485-6 [7567757.001]
  • [Cites] Histopathology. 1986 Feb;10(2):119-33 [3007321.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):752-60 [11395552.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1677-82 [18059224.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):499-506 [17033797.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S29-38 [17684762.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):773-81 [9287968.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Apr;52(4):820-2 [7204545.001]
  • [Cites] World J Surg. 1996 Feb;20(2):183-8 [8661815.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):1-9 [2750701.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(3):263-9 [6115499.001]
  • (PMID = 17684761.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 176
  •  go-up   go-down


29. Culig Z, Steiner H, Bartsch G, Hobisch A: Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem; 2005 Jun 1;95(3):497-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 regulation of prostate cancer cell growth.
  • Interleukin-6 (IL-6) is involved in regulation of immune reaction and cell growth and differentiation.
  • It causes multifunctional responses ranging from inhibition of proliferation to promotion of cell survival.
  • IL-6 is expressed in benign and malignant prostate tissue and the levels of the cytokine and its receptor increase during prostate carcinogenesis.
  • The only exemption seems to be the LNCaP cell line, in which IL-6 causes growth arrest and induces differentiation function.
  • Activation of signaling pathways of Janus kinase/signal transducers and activators of transcription factors, mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase has been reported in various prostate cancer cell lines.
  • IL-6 is also involved in regulation of vascular endothelial growth factor expression as well as neuroendocrine differentiation in prostate.
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Male. Receptors, Androgen / metabolism


30. Krishna NB, LaBundy JL, Saripalli S, Safdar R, Agarwal B: Diagnostic value of EUS-FNA in patients suspected of having pancreatic cancer with a focal lesion on CT scan/MRI but without obstructive jaundice. Pancreas; 2009 Aug;38(6):625-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Patients frequently present with suspected pancreatic neoplasm based on a focal pancreatic lesion on computed tomographic (CT) scan/magnetic resonance image (MRI) but without obstructive jaundice.
  • The final diagnosis included adenocarcinoma (n=89), neuroendocrine tumor (n=14), mucinous cystadenocarcinoma (n=1), solid pseudopapillary tumor (n=2), metastases (n=4), benign cyst (n=19), pseudocyst (n=9), abscess (n=4), chronic pancreatitis (n=32), and normal pancreas (n=39).
  • Endoscopic ultrasound-guided FNA had an accuracy of 97.6% for diagnosing malignant neoplasm, with 96.6% sensitivity, 99.0% specificity, 96.2% negative predictive value, and 99.1% positive predictive value.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Endosonography / methods. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Databases, Factual. Diagnosis, Differential. Female. Humans. Jaundice, Obstructive / diagnosis. Magnetic Resonance Imaging. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506529.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Louthan O: [Neuroendocrine tumours of the appendix]. Vnitr Lek; 2009 Nov;55(11):1051-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine tumours of the appendix].
  • According to WHO, neuroendocrine tumors of the appendix (appendiceal carcinoids) are defined as 1. well-differentiated endocrine tumors with benign or uncertain behavior, 2. well-differentiated endocrine carcinoma and 3. goblet cell carcinoma.
  • These tumors are usually diagnosed incidentally during appendectomy.
  • Tumor size greater than 2 cm is the most important parameter for prognosis.
  • Most patients are cured by appendectomy (appendiceal tumors < or = 2 cm), tumors with a diameter > 2 cm should be managed by right hemicolectomy.
  • [MeSH-major] Appendiceal Neoplasms. Neuroendocrine Tumors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017436.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 26
  •  go-up   go-down


32. Soslow RA: Mixed Müllerian Tumors of the Female Genital Tract. Surg Pathol Clin; 2009 Dec;2(4):707-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed Müllerian Tumors of the Female Genital Tract.
  • Malignant mixed müllerian tumor (MMMT) and müllerian/mesodermal adenosarcoma are 2 of the most common mixed müllerian tumors of the female genital tract.
  • MMMT is a biphasic neoplasm, composed of morphologically malignant epithelial and stromal components.
  • MMMT should be distinguished from endometrioid adenocarcinoma with spindle cell elements, "dedifferentiated" endometrioid carcinoma, and combined adenocarcinoma and neuroendocrine carcinoma.
  • Adenosarcoma is also biphasic; it is composed of morphologically benign or low-grade appearing epithelial components and malignant stromal components.
  • The differential diagnosis of adenosarcoma includes MMMT, endometrial stromal tumor containing endometrioid glands, benign endometrial or endocervical polyp, adenofibroma, adenomyoma, including atypical polypoid adenomyoma, botryoid embryonal rhabdomyosarcoma (sarcoma botryoides), and endometriosis, including polypoid endometriosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Inc. All rights reserved.
  • (PMID = 26838776.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenofibroma / Atypical polypoid adenomyoma / Carcinosarcoma / Female genital tract / Low-grade müllerian/mesodermal adenosarcoma / Malignant mixed mesodermal / Malignant mixed müllerian tumor / Polypoid endometriosis
  •  go-up   go-down


33. Lehwald N, Cupisti K, Baldus SE, Kröpil P, Schulte Am Esch J 2nd, Eisenberger CF, Knoefel WT: Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series. J Med Case Rep; 2010;4:402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual histological findings after partial pancreaticoduodenectomy including benign multicystic mesothelioma, adenomyoma of the ampulla of Vater, and undifferentiated carcinoma, sarcomatoid variant: a case series.
  • Pathology revealed a benign multicystic mesothelioma.
  • Endoscopic retrograde cholangiopancreatographic examination and a computed tomography scan showed a stenosis of the distal bile duct secondary to a mass in the head of the pancreas and duodenum.
  • CONCLUSION: Partial pancreaticoduodenectomy is usually performed for ductal adenocarcinomas, neuroendocrine tumors or chronic pancreatitis.
  • Benign multicystic mesothelioma is a very rare tumor that originates from the peritoneum.
  • Although it demonstrates a benign clinical behaviour, it frequently recurs after resection.
  • Adenomyoma of the bile duct or ampullary region is a very unusual, benign, localized lesion characterized by adenomyomatous hyperplasia.
  • Undifferentiated carcinoma, sarcomatoid variant, is an aggressive tumor and is characterized by spindle cells.
  • The histologic diagnosis after partial pancreaticoduodenectomy may differ from the preoperative and intraoperative findings.
  • These cases demonstrate that a definitive diagnosis may only be obtained by a pathologic examination of the surgical specimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(1):98-100 [10648095.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):530-6 [12808057.001]
  • [Cites] Surg Today. 2008;38(1):85-9 [18085373.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Pancreas. 2005 Oct;31(3):291-2 [16163064.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):547-50 [7550871.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Surg Gynecol Obstet. 1978 Jun;146(6):959-62 [653575.001]
  • [Cites] Am J Obstet Gynecol. 1983 Feb 1;145(3):355-9 [6824025.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1615-22 [7116294.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • (PMID = 21143956.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016302
  •  go-up   go-down


34. Simon P, Spilcke-Liss E, Wallaschofski H: Endocrine tumors of the pancreas. Endocrinol Metab Clin North Am; 2006 Jun;35(2):431-47, xii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumors of the pancreas.
  • Neuroendocrine tumors of the pancreas are rare neoplasms of the heterogeneous group of neuroendocrine gastroenteropancreatic tumors that originate from totipotential stem cells or preexisting endocrine cells within the pancreas.
  • Most neuroendocrine tumors of the pancreas are benign or show an indolent course of disease.A subset of them shows a very aggressive behavior, becomes highly malignant, and metastasizes early with life-limiting consequences.
  • An effective disease-management includes the diagnostic approach with hormonal testing and localization and surgical treatment with histologic classification in combination with biotherapy, chemotherapy, or therapy with radionucleotides, de-pending on the individual behavior of the tumor.
  • [MeSH-major] Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Diagnostic Imaging. Drug Therapy. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632104.001).
  • [ISSN] 0889-8529
  • [Journal-full-title] Endocrinology and metabolism clinics of North America
  • [ISO-abbreviation] Endocrinol. Metab. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


35. Rott G, Biggemann M, Pfohl M: Embolization of an insulinoma of the pancreas with trisacryl gelatin microspheres as definitive treatment. Cardiovasc Intervent Radiol; 2008 May-Jun;31(3):659-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulinomas are rare, mostly benign neuroendocrine tumors, originating in 99% of cases from the pancreas, that synthesize and secrete insulin, causing symptomatic hypoglycemia.

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922161.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / trisacryl gelatin microspheres; 9000-70-8 / Gelatin
  •  go-up   go-down


36. Balaa FK, Gamblin TC, Tsung A, Marsh JW, Geller DA: Right hepatic lobectomy using the staple technique in 101 patients. J Gastrointest Surg; 2008 Feb;12(2):338-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of those with cancer, 78% (69 of 89) had metastatic colorectal cancer, 6% (5 of 89) had metastatic neuroendocrine tumor, 4% (4 of 89) had hepatocellular carcinoma, 4% (4 of 89) had cholangiocarcinoma, and the remaining 8% were other metastatic cancers.
  • Twelve patients (12%) underwent resection for hepatic adenoma or symptomatic benign disease (FNH or hemangioma).
  • All patients with malignant disease had tumor-free margins at the completion of the procedure.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Jan;131(1):104-6 [8546569.001]
  • [Cites] Surgery. 1995 Feb;117(2):140-5 [7846617.001]
  • [Cites] Colorectal Dis. 2004 May;6(3):165-70 [15109380.001]
  • [Cites] Am Surg. 2000 Nov;66(11):1037-40 [11090014.001]
  • [Cites] Am J Surg. 1994 Jul;168(1):49-53 [8024098.001]
  • [Cites] J Am Coll Surg. 2001 Aug;193(2):210-22 [11491452.001]
  • [Cites] HPB (Oxford). 2005;7(3):208-13 [18333192.001]
  • [Cites] J Am Coll Surg. 1994 May;178(5):510-1 [8167890.001]
  • [Cites] Liver Int. 2007 Feb;27(1):26-39 [17241378.001]
  • [Cites] Asian J Surg. 2003 Oct;26(4):193-6 [14530102.001]
  • [Cites] Am J Surg. 1989 Nov;158(5):459-60 [2817228.001]
  • [Cites] Surg Obes Relat Dis. 2006 Nov-Dec;2(6):669 [17138242.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):280-4 [14769320.001]
  • [Cites] J Chir (Paris). 1990 Jun-Jul;127(6-7):356-8 [2211893.001]
  • [Cites] Surg Endosc. 2004 Jun;18(6):961-3 [15108116.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):40-1 [1998861.001]
  • [Cites] J Urol. 1993 Jun;149(6):1437-9; discussion 1439-40 [8501782.001]
  • [Cites] ANZ J Surg. 2003 Nov;73(11):922-5 [14616571.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):93-100 [9208969.001]
  • [Cites] Surg Obes Relat Dis. 2006 Jul-Aug;2(4):431-4 [16925374.001]
  • [Cites] Am J Surg. 1996 Oct;172(4):358-62 [8873530.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):299-303 [10606173.001]
  • [Cites] Am J Surg. 2005 Jul;190(1):23-9 [15972166.001]
  • [Cites] Obes Surg. 2003 Dec;13(6):855-9; discussion 860 [14738669.001]
  • [Cites] Obes Surg. 2006 Dec;16(12):1559-62 [17217629.001]
  • [Cites] Surg Technol Int. 1998;7:43-7 [12721961.001]
  • [Cites] J Invest Surg. 1997 Jan-Apr;10(1-2):59-61 [9100177.001]
  • [Cites] World J Surg. 2006 Mar;30(3):419-30 [16467982.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1697-700 [12820443.001]
  • [Cites] S Afr J Surg. 1992 Jun;30(2):47-8 [1519125.001]
  • (PMID = 17701266.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Visser BC, Muthusamy VR, Yeh BM, Coakley FV, Way LW: Diagnostic evaluation of cystic pancreatic lesions. HPB (Oxford); 2008;10(1):63-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cystic pancreatic neoplasms (CPNs) present a unique challenge in preoperative diagnosis.
  • MATERIAL AND METHODS: This retrospective cases series includes 70 patients who underwent surgery at a university hospital for presumed CPNs between 1997 and 2003, and for whom a definitive diagnosis was established.
  • RESULTS: The final histopathologic diagnoses were mucinous cystic neoplasm (n=13), mucinous cystadenocarcinoma (10), serous cystadenoma (11), IPMN (14), simple cyst (3), cystic neuroendocrine tumor (5), pseudocyst (4), and other (10).
  • Overall, 25 of 70 were malignant (37%), 21 premalignant (30%), and 24 benign (34%).
  • The attending surgeon's preoperative diagnosis was correct in 31% of cases, incorrect in 29%, non-specific "cystic tumor" in 27%, and "pseudocyst vs. neoplasm" in 11%.
  • In review of the CT and MRI, a multivariate analysis of the morphologic features did not identify predictors of specific pathologic diagnoses.
  • Both radiologists were accurate with their preferred (no. 1) diagnosis in <50% of cases.
  • CONCLUSIONS: The diagnosis of CPN remains challenging.
  • Cross-sectional imaging methods do not reliably give an accurate preoperative diagnosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 1998 Jul-Aug;23(4):387-93 [9663274.001]
  • [Cites] Radiology. 2003 Sep;228(3):727-33 [12954892.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):967-70 [8884322.001]
  • [Cites] Surgery. 1996 Mar;119(3):275-80 [8619182.001]
  • [Cites] AJR Am J Roentgenol. 1995 Apr;164(4):815-9 [7537015.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1230-5 [7535275.001]
  • [Cites] Radiology. 1993 Sep;188(3):633-6 [8394590.001]
  • [Cites] Ann Surg. 1993 Jan;217(1):41-7 [8424699.001]
  • [Cites] Int J Biol Markers. 1990 Jul-Sep;5(3):127-32 [2286776.001]
  • [Cites] AJR Am J Roentgenol. 1988 Dec;151(6):1133-8 [3055888.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):393-8 [3566376.001]
  • [Cites] Radiology. 1983 Oct;149(1):45-50 [6611949.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1323-4 [14535994.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Lancet. 1952 Sep 13;2(6733):505-9 [12981885.001]
  • [Cites] Gut. 1999 Nov;45(5):737-40 [10517912.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2421-4 [9951936.001]
  • [Cites] Endoscopy. 1998 Aug;30 Suppl 1:A108-10 [9765099.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):59-64 [12838222.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Pancreas. 2002 Oct;25(3):222-8 [12370531.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4 Suppl):S91-3 [12297757.001]
  • [Cites] Am J Gastroenterol. 2001 Dec;96(12):3295-300 [11774939.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] AJR Am J Roentgenol. 2001 Apr;176(4):921-9 [11264079.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6 Suppl):S18-22 [11115943.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):961-5 [10763945.001]
  • [Cites] Clin Radiol. 2000 Mar;55(3):187-92 [10708611.001]
  • [Cites] Abdom Imaging. 2000 Mar-Apr;25(2):201-6 [10675468.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):205-12 [10674612.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Md Med J. 1997 Feb;46(2):79-82 [9029906.001]
  • (PMID = 18695762.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2504857
  • [Keywords] NOTNLM ; Computed tomography (CT) / cystadenocarcinoma / cystadenoma / cystic / magnetic resonance (MR) / mucinous / neoplasm / pancreas / serous
  •  go-up   go-down


38. Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J: Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology; 2006 Jun;67(6):1247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
  • OBJECTIVES: To evaluate the expression of chromogranin A, a marker for neuroendocrine (NE) differentiation, in patients with lymph node-positive prostate cancer to determine its prognostic significance.
  • Immunohistochemical staining for chromogranin A was evaluated in areas of benign epithelium, primary prostate cancer, and lymph node metastasis.
  • RESULTS: Staining was positive in 86% of benign areas, 61% of primary cancer specimens, and 12% of lymph node deposits.
  • The preoperative serum prostate-specific antigen level and pathologic stage and grade of the primary tumor did not show any statistically significant correlation with NE staining in any of the areas.
  • Only NE expression in the primary tumor was associated with clinical recurrence, with a 10-year recurrence-free survival rate for those with less than 5% staining of 67% compared with 35% for those with 5% staining or greater (P = 0.03).
  • Furthermore, after adjusting for age, greater NE expression in the primary tumor (relative risk 2.15, P = 0.02) and lymph node deposit (relative risk 2.03, P = 0.03) was associated with poorer overall survival.
  • CONCLUSIONS: NE expression in the primary tumor and lymph node metastasis of patients with node-positive prostate cancer may provide additional prognostic stratification.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / biosynthesis. Chromogranins / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology


39. Kemeny AA: Contemporary management of jugular paragangliomas (glomus tumours): microsurgery and radiosurgery. Acta Neurochir (Wien); 2009 May;151(5):419-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary management of jugular paragangliomas (glomus tumours): microsurgery and radiosurgery.
  • [MeSH-major] Glomus Jugulare Tumor / surgery. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Acta Neurochir (Wien). 2009 May;151(5):423-6 [19296050.001]
  • (PMID = 19296051.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Austria
  •  go-up   go-down


40. Hanaoka T, Sone S, Ino H, Takayama F, Sato T, Kanaya H, Ogata H: Subcentimeter large cell neuroendocrine carcinoma of the lung. J Thorac Imaging; 2005 Nov;20(4):288-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcentimeter large cell neuroendocrine carcinoma of the lung.
  • To our knowledge, no report exists of a subcentimeter size large cell neuroendocrine carcinoma (LCNEC) of the lung.
  • The final diagnosis was stage IA-LCNEC.
  • The estimated volume doubling time of the tumor was 30.1 days.
  • These aggressive tumors may rarely have doubling times that overlap with benign processes.
  • [MeSH-major] Carcinoma, Large Cell / radiography. Carcinoma, Neuroendocrine / radiography. Lung Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282907.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Al-Harthy M, Al-Harthy S, Al-Otieschan A, Velagapudi S, Alzahrani AS: Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas. Endocr Pract; 2009 Apr;15(3):194-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas.
  • OBJECTIVE: To compare clinical, radiologic, and pathologic characteristics, as well as management and outcomes, in a series of pheochromocytomas, abdominal and pelvic paragangliomas, and pelvic paragangliomas with head and neck paragangliomas.
  • We searched pathology and medical record databases under the terms pheochromocytoma, paraganglioma, head and neck tumors, carotid body tumors, glomus jugulare, and neuroendocrine tumors.
  • We compared clinical, radiologic, and pathologic characteristics, as well as management and outcomes, between patients with pheochromocytoma, abdominal and pelvic paraganglioma, and head and neck paraganglioma.
  • RESULTS: Eighty-six patients were included (46 with head and neck paraganglioma, 23 with pheochromocytoma, and 17 with abdominal or pelvic paraganglioma).
  • Compared with patients with head and neck paraganglioma, patients with pheochromocytoma or abdominal and pelvic paraganglioma were younger (35.7 +/- 16 years vs 43 +/- 17 years, P = .042) and were more likely to have the classic triad associated with catecholamine hypersecretion of palpitation, excessive sweating, and headache (40% vs 0%, P<.001); hypertension (70% vs 37%, P = .005); and benign tumors (65% vs 43%, P = .03).
  • Patients with head and neck paraganglioma and patients with pheochromocytoma/abdominal and pelvic paraganglioma were not different in female to male ratios (27:19 vs 29:11, respectively, P = .18), tumor size (5.8 +/- 2.7 cm vs 5.7 +/- 3 cm, respectively; P = .85), or remission rate (43% vs 60%, respectively, P = .13).
  • CONCLUSIONS: Head and neck paraganglioma are similar to pheochromocytoma and abdominal and pelvic paraganglioma in size and outcome, but occur at an older age, lack hyperadrenergic manifestations, and are more likely to have local pressure effects and result in persistent disease.
  • [MeSH-major] Abdominal Neoplasms / epidemiology. Adrenal Gland Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Paraganglioma / epidemiology. Pelvic Neoplasms / epidemiology. Pheochromocytoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Comorbidity. Disease Progression. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364686.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg; 2006 Dec;244(6):845-51; discussion 852-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors.
  • OBJECTIVE: To evaluate the outcome of reoperations in patients with duodenopancreatic neuroendocrine tumors (PETs) in a tertiary referral center.
  • The diagnosis of PETs was based on clinical symptoms, biochemical tests, and histopathology.
  • RESULTS: A total of 33 patients with a median age of 42 years were identified for this study: 13 patients had gastrinomas, 12 patients had nonfunctional islet cell tumors, 6 patients had insulinomas, and 2 patients had vipomas; 24 patients had sporadic NETs, 9 patients had a MEN-1-syndrome; 27 patients had histologically verified malignant tumors; 33 initial operations and 50 reoperations were performed.
  • The initial procedures comprised 27 resections of the primary tumor and 6 explorative laparotomies; 28 of all reoperations were resections of distant metastases, including 15 liver resections; 19 resections of the pancreas or duodenum were performed during reoperations.
  • All 6 patients with benign tumors are still alive.
  • The 5-, 10-, and actuarial 25-year survival rate for patients with malignant tumors were 81%, 72%, and 36%, respectively.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Nov;24(11):1418-24 [11038216.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Cancer Control. 2002 Jan-Feb;9(1):67-79 [11907468.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):855-62 [12417506.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):29-37 [12831921.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):859-66 [12912744.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Apr 23;129(17):941-6 [15083396.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):757-73 [15492556.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Surgery. 1988 Dec;104(6):1011-7 [2904180.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):393-8; discussion 398-9 [1973323.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Aug;73(2):281-7 [1677362.001]
  • [Cites] Arch Surg. 1993 Jun;128(6):683-90 [8099273.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):320-8; discussion 328-30 [7916560.001]
  • [Cites] World J Surg. 1998 Jun;22(6):581-6; discussion 586-7 [9597932.001]
  • [Cites] World J Surg. 1998 Jul;22(7):666-71; discussion 671-2 [9606279.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):495-500 [9681848.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):286-93 [9922308.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):615-30 [10080607.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1353-60 [11038206.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):36-42; discussion 42-3 [7817996.001]
  • [Cites] World J Surg. 1996 Sep;20(7):908-14; discussion 914-5 [8678970.001]
  • [Cites] Surgery. 1996 Dec;120(6):1055-62; discussion 1062-3 [8957495.001]
  • [Cites] Gut. 2005 Feb;54(2):289-96 [15647196.001]
  • [Cites] Surgery. 2004 Dec;136(6):1205-11 [15657577.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):170-85 [15719379.001]
  • [Cites] Chirurg. 2005 Mar;76(3):217-26 [15688179.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):577-83 [16183528.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):699-704 [16253894.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81 [16253899.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):783-98 [16253900.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):819-30 [16253903.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6 [16327485.001]
  • [Cites] Surgery. 2001 Feb;129(2):170-5 [11174710.001]
  • (PMID = 17122609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1856628
  •  go-up   go-down


43. Ligato S, Mandich D, Cartun RW: Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod Pathol; 2008 May;21(5):626-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the immunocytochemical expression of GPC3 in archival material obtained from fine needle aspiration of hepatic lesions to assess the sensitivity and specificity of this marker in cytological material and its potential diagnostic utility in differentiating hepatocellular carcinoma (HCC) from other primary benign or malignant hepatic tumors and from metastatic lesions in the liver.
  • Cytological diagnoses (confirmed by tissue diagnosis and/or clinical follow-up) included: 7 adenomas, 1 focal nodular hyperplasia (FNH), 24 HCCs, and 17 metastatic tumors.
  • The only case expressing GPC3 was an anaplastic carcinoma with neuroendocrine features of unknown origin.
  • In this study, the sensitivity of GPC3 in the diagnosis of HCC in the cytological material was 83.3%, the specificity 96%, the positive predictive value (PPV) 95% and negative predictive value (NPV) was 85.7%.
  • Immunocytochemical staining for GPC3 in alcohol-fixed FNA material is a highly sensitive and specific method capable of distinguishing HCC from other benign and malignant hepatic lesions and from the great majority of metastatic lesions.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / diagnosis. Glypicans / biosynthesis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264086.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


44. Cavigelli SA, Yee JR, McClintock MK: Infant temperament predicts life span in female rats that develop spontaneous tumors. Horm Behav; 2006 Sep;50(3):454-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant temperament predicts life span in female rats that develop spontaneous tumors.
  • To minimize the variance of disease processes at the end of life, we conducted a longitudinal study with female Sprague-Dawley rats prone to high rates of spontaneous mammary and pituitary tumors.
  • For females that developed either mammary or pituitary tumors, those that had been neophobic (least exploratory) as infants died approximately 6 months earlier than their neophilic (most exploratory) sisters.
  • In the case of mammary tumors, both benign and malignant, neophobic females developed palpable tumors earlier than neophilic females, whereas the interval between first palpation and death was the same for all females, indicating psychosocial regulation of early rather than later stages of the disease.
  • During puberty, when mammary tissue is proliferating and differentiating, neophobic females experienced more irregular cycles with prolonged "luteal" phases, suggesting a role for prolactin, prolonged progesterone and fewer estrogen surges during this sensitive period for mammary tumor risk.
  • Thus, we identified prolactin, estrogen, progesterone and possibly corticosterone dynamics as candidates for neuroendocrine mechanisms linking infant temperament with onset of adult neoplastic disease.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836996.001).
  • [ISSN] 0018-506X
  • [Journal-full-title] Hormones and behavior
  • [ISO-abbreviation] Horm Behav
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / F32 HD008693; United States / NICHD NIH HHS / HD / F32 HD08693; United States / NIA NIH HHS / AG / P01 AG018911; United States / NIMH NIH HHS / MH / R37 MH41788
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


45. Carrizo F, Pineda-Daboin K, Neto AG, Luna MA: Pharyngeal teratocarcinosarcoma: review of the literature and report of two cases. Ann Diagn Pathol; 2006 Dec;10(6):339-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratocarcinosarcomas are rare malignant neoplasms histologically characterized by the presence of benign and malignant epithelial and mesenchymal elements.
  • The tumors consisted of epithelial components including squamous, neuroendocrine, and glandular structures; neuroepithelium, and mesenchymal components with prominent rhabdomyoblastic, osteoblastic and chondroid differentiation.
  • The tumors were resected, and the patients received postoperative radiation therapy.
  • One patient is alive with recurrent tumor 33 months after treatment and the other died 26 months after radiation therapy with distant metastasis.
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pharyngectomy. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126251.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Thouënnon E, Elkahloun AG, Guillemot J, Gimenez-Roqueplo AP, Bertherat J, Pierre A, Ghzili H, Grumolato L, Muresan M, Klein M, Lefebvre H, Ouafik L, Vaudry H, Plouin PF, Yon L, Anouar Y: Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab; 2007 Dec;92(12):4865-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Pheochromocytomas are catecholamine-producing tumors that are generally benign but that can also present as or develop into malignancy.
  • OBJECTIVES: We conducted a gene expression profiling of benign and malignant tumors to identify a gene signature that would allow us to discriminate benign from malignant pheochromocytomas and to gain a better understanding of tumorigenic pathways associated with malignancy.
  • There were 18 (nine benign and nine malignant) tumors used for gene expression profiling on pangenomic oligonucleotide microarrays.
  • RESULTS: We identified and validated a set of predictor genes that could accurately distinguish the two tumor subtypes through unsupervised clustering.
  • Most of the differentially expressed genes were down-regulated in malignant tumors, and several of these genes encoded neuroendocrine factors involved in prominent characteristics of chromaffin cell biology.
  • CONCLUSION: The gene expression profiling of benign and malignant pheochromocytomas clearly identified a set of genes that could be used as a prognostic multi-marker and revealed that the expression of several genes encoding neuroendocrine proteins was reduced in malignant compared with benign tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Genetic Markers. Humans. Infant. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878247.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / RNA, Neoplasm
  •  go-up   go-down


47. Hartley N, Rajesh A, Verma R, Sinha R, Sandrasegaran K: Abdominal manifestations of neurofibromatosis. J Comput Assist Tomogr; 2008 Jan-Feb;32(1):4-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations of the NF gene lead to abnormal tumor suppression.
  • Consequently, NF is a complex disease, with patients having an increased prevalence of benign and malignant neoplasms throughout the body.
  • We present cases of the most common abdominal presentations: neurofibroma, malignant peripheral nerve sheath tumor, pheochromocytoma, carcinoid, gastrointestinal stromal tumor, and seminoma.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Endocrine Gland Neoplasms / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Nerve Sheath Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis. Neurofibromatosis 1 / complications. Seminoma / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303281.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


48. Teh SH, Deveney C, Sheppard BC: Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg; 2007 May;193(5):610-3; discussion 613
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
  • BACKGROUND: Benign and malignant pancreatic neuroendocrine tumors (PNETs) are rare, and long-term outcome is generally poor without surgical intervention.
  • There were 20 benign (9 functional) and 13 malignant (6 functional) neoplasms.
  • Mean tumor size was 4.2 cm, and multiple tumors were noted in 10 patients.
  • The 1-, 3-, and 5-year overall survival rates for patients with benign versus malignant neoplasms were 100% vs. 92%, 89% vs. 64%, and 89% vs 36% (P = .01), respectively.
  • [MeSH-major] Neuroendocrine Tumors / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery


49. de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP: Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest; 2005;28(11 Suppl International):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors and somatostatin: imaging techniques.
  • Tumors and metastases bearing the somatostatin receptor subtypes 2 (SSTR2) or SSTR5 can be visualized in vivo after injection of radiolabeled octapeptide somatostatin analogs like 111In-pentetreotide.
  • The sensitivity of 111In-pentetreotide scintigraphy for the detection of carcinoid tumors is 86-95%.
  • The sensitivity of 111In-pentetreotide scintigraphy for the detection of gastrinomas, vasoactive intestinal polypeptide-secreting tumors, and glucagonomas as well as clinically non-functioning lesions is 75-100%.
  • 111In-pentetreotide scintigraphy generally has a lower detection rate for benign pheochromocytomas than 123I-MIBG scintigraphy, but it can have a complementary role for the staging of malignant pheochromocytomas.
  • It can also be used for the detection of extra-adrenal pheochromocytomas and paragangliomas.
  • 111In-pentetreotide scintigraphy has been successful for the localization of extra-pituitary ACTH-secreting tumors and their metastases, and especially for occult tumors.
  • [MeSH-major] Neuroendocrine Tumors / radionuclide imaging. Somatostatin
  • [MeSH-minor] Carcinoid Tumor / radionuclide imaging. Gastrointestinal Neoplasms / radionuclide imaging. Humans. Indium Radioisotopes. Paraganglioma / radionuclide imaging. Pheochromocytoma / radionuclide imaging. Pituitary Neoplasms / radionuclide imaging. Receptors, Somatostatin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625862.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide
  • [Number-of-references] 49
  •  go-up   go-down


50. Andronesi D, Andronesi A, Tonea A, Andrei S, Herlea V, Lupescu I, Ionescu-Târgovişte C, Coculescu M, Fica S, Ionescu M, Gheorghe C, Popescu I: [Insulinoma of the pancreas: analysis of a clinical series of 30 cases]. Chirurgia (Bucur); 2009 Nov-Dec;104(6):675-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulinoma is the most frequent neuroendocrine pancreatic tumor and is the main cause for hypoglicemia due to endogenous hyperinsulinism.
  • We performed an analysis of a clinical series in order to study the clinical and biological spectrum of presentation, the preoperatory imagistic diagnosis and results of the surgical approach.
  • Before the intraoperatory ultrasound was used the tumor excision was predominantly done by extensive pancreatic resection, while after this was available in our centre more conservative (enucleo-resection) procedures were chosen.
  • The dimensions of the tumor were less than 2 cm in most of the patients; 2 had nesidioblastosis and 2 had multiple insulinomas; all 28 patients proved to have benign insulinomas at histological specimens.
  • CONCLUSIONS: Due to small dimensions, the preoperative diagnosis of insulinomas is usually difficult, ecoendoscopy being the most sensitive method.
  • In benign insulinomas the prognosis is excellent, surgical resection being curative in all cases.

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187465.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


51. Graham RP, Williams NP, West KA: Primary epithelial tumours of the appendix in a black population: a review of cases. World J Gastroenterol; 2009 Mar 28;15(12):1472-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelial tumours of the appendix in a black population: a review of cases.
  • AIM: To determine the prevalence, histologic types and clinical features of primary epithelial tumours of the vermiform appendix in a predominantly black population.
  • METHODS: All cases of primary tumours of the appendix identified by review of the histopathology records at the University of the West Indies between January 1987 and June 2007 were selected.
  • Non-epithelial tumours were excluded.
  • RESULTS: Forty-two primary epithelial tumours were identified out of 6,824 appendectomies yielding a prevalence rate of approximately 0.62%.
  • Well-differentiated neuroendocrine cell tumours (carcinoids, 47.6%) and benign non-endocrine cell tumours (adenomas, 45.2%) were most common with nearly equal frequency.
  • Carcinoid tumours occurred in younger patients (mean age 32 years), with a male-to-female ratio of 1.2:1.
  • A clinical diagnosis of acute appendicitis was the most common reason for appendectomy (57.1%) and was histologically confirmed in 75% (18 of 24) of cases.
  • CONCLUSION: Appendiceal epithelial tumours are rare in our experience, and are represented principally by carcinoid tumours and adenomas.
  • Carcinoid tumours occurred in younger patients but were slightly more common in men than women.
  • Tumours were not suspected clinically and were diagnosed incidentally in specimens submitted for acute appendicitis supporting the need for histological evaluation in all resection specimens.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenoma / epidemiology. Adenoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / epidemiology. Carcinoid Tumor / pathology. Female. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. West Indies / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Histopathology. 1992 Nov;21(5):447-51 [1452128.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):299-306 [7795991.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1856-9 [17763906.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38 [16253897.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2264-71 [16258711.001]
  • [Cites] World J Gastroenterol. 2006 Nov 7;12(41):6699-701 [17075987.001]
  • [Cites] Int J Clin Pract. 2007 Mar;61(3):431-7 [16911574.001]
  • [Cites] BMC Surg. 2007;7:17 [17692116.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):422-8 [9517651.001]
  • (PMID = 19322920.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2665141
  •  go-up   go-down


52. Alasio TM, Vine A, Sanchez MA, Dardik H: Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature. Ann Diagn Pathol; 2005 Aug;9(4):234-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature.
  • Serous cystadenomas of the pancreas have been classified as benign exocrine tumors.
  • We report a case of a coexistent neuroendocrine tumor identified within a serous cystadenoma in a 78-year-old woman, which was discovered incidentally after complete resection of the tumor.
  • Given the unpredictable metastatic potential of neuroendocrine tumors of the pancreas, we advocate complete resection of all pancreatic cystic tumors, combined with careful sampling of the pathological specimen to rule out a coexistent potentially malignant neoplasm.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084460.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Rimbot A, Mounayer C, Loureiro C, Queiroz C, Kadziolka K, Spelle L, Piotin M, Bozorg-Grayeli A, Moret J: [Preoperative mixed embolization of a paraganglioma using Onyx]. J Neuroradiol; 2007 Dec;34(5):334-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative mixed embolization of a paraganglioma using Onyx].
  • [Transliterated title] Embolisation préopératoire par abord mixte d'un paragangliome à l'aide d'Onyx.
  • Paragangliomas, or glomus tumors, are highly vascular benign tumors of the head and neck.
  • Preoperative embolization can reduce morbidity, and several techniques have been described using arterial injection of particles or of cyanoacrylate directly into the tumor.
  • This case report is of a patient treated by surgery using a new technique-preoperative embolization involving both the arteries and veins, and injection of Onyx, resulting in complete devascularization of the tumor's arteriovenous network.
  • [MeSH-major] Dimethyl Sulfoxide / administration & dosage. Embolization, Therapeutic / methods. Head and Neck Neoplasms / therapy. Paraganglioma / therapy. Polyvinyls / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988740.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Onyx copolymer; 0 / Polyvinyls; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


54. Tongson-Ignacio JE, Honda SA, Bhagavan NV: Insulinoma, a rare neuroendocrine tumor: a case report. Hawaii Med J; 2005 Jan;64(1):9-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulinoma, a rare neuroendocrine tumor: a case report.
  • We report a case of Insulinoma, a rare neuroendocrine tumor with an incidence of approximately four per 5 million.
  • This case demonstrates the characteristic clinical, biochemical and histological features of an insulinoma, a rare benign neuroendocrine tumor where early recognition is important to ensure proper surgical treatment and prevent serious adverse consequences.


55. Kolb A, Kleeff J, Frohlich B, Werner J, Friess H, Büchler MW: Resection of the intrapancreatic bile duct preserving the pancreas. J Hepatobiliary Pancreat Surg; 2009;16(1):31-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign neoplasms of the distal bile duct are rare, but pose a therapeutic challenge.
  • Here, we present a case of an intrapancreatic benign neuroendocrine tumor that was resected by performing a pancreas-preserving distal bile duct resection.
  • First, a duodenotomy was carried out and a probe was inserted into the pancreatic duct to avoid inadvertent injury.
  • The duodenal incision was closed, and reconstruction was performed by an end-to-side hepaticojejunostomy and a Roux-Y jejunojejunostomy.
  • In conclusion, pancreas-preserving distal bile duct resection might be an option for intrapancreatic benign lesions of the distal bile duct that would otherwise require a partial pancreaticoduodenectomy.
  • [MeSH-major] Carcinoma, Neuroendocrine / surgery. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19089312.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Chetty R, Perez-Ordonez B, Gilbert R, Pagedar NA, Waldron J, Ghazarian D: Spiradenocarcinoma arising from a spiradenocylindroma: unusual case with lymphoepithelioma-like areas. J Cutan Med Surg; 2009 Jul-Aug;13(4):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hybrid skin adnexal tumors are common, and spiradenocylindroma is well described.
  • METHODS: A 65-year-old female presented with ataxia and a skin nodule composed of a hybrid adnexal tumor (spiradenoma and cylindroma) that transitioned into an undifferentiated carcinoma with attendant lymphocytes and plasma cells.
  • The tumor was Epstein-Barr encoded RNAs (EBER) negative by in situ hybridization.
  • No evidence of neuroendocrine differentiation was seen in the tumor, despite the patient having symptoms of paraneoplastic ataxia that improved after surgery.
  • CONCLUSION: This case highlights the transition of a benign hybrid tumor (spiradenocylindroma) into a spiradenocarcinoma that resembled lymphoepithelioma-like carcinoma of skin.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706230.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y: Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol; 2007 Jun;29(3):128-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Function and molecular mechanisms of neuroendocrine cells in prostate cancer.
  • Benign prostate contains luminal epithelial cells, basal cells and a minor component of neuroendocrine cells whose function may be to regulate the growth, differentiation and secretory function of the prostate gland.
  • Neuroendocrine (NE) cells are also present in prostate cancer (PC), and many studies have shown that their number increases in high-grade and high-stage tumors, particularly in hormonally treated and hormone-refractory (androgen independent) PC.
  • Unlike the non-neuroendocrine secretory-type PC cells, NE cells lack androgen receptor and are likely androgen independent.
  • Instead, these cells may be enriched after the therapy and they may establish paracrine networks to stimulate androgen-independent proliferation of PC, leading to tumor recurrence.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672372.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


58. Abbas F, Memon A, Siddiqui T, Kayani N, Ahmad NA: Granular cell tumors of the urinary bladder. World J Surg Oncol; 2007;5:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the urinary bladder.
  • BACKGROUND: Granular cell tumors (GCTs) are extremely rare lesions of the urinary bladder with only nine cases being reported in world literature of which one was malignant.
  • Generally believed to be of neural origin based on histochemical, immunohistochemical, and ultrastructural studies; they mostly follow a clinically benign course but are commonly mistaken for malignant tumors since they are solid looking, ulcerated tumors with ill-defined margins.
  • MATERIALS AND METHODS: We herein report two cases of GCTs, one benign and one malignant, presenting with gross hematuria in a 14- and a 47-year-old female, respectively.
  • RESULTS: Histopathology revealed characteristic GCTs with positive immunostaining for neural marker (S-100) and negative immunostaining for epithelial (cytokeratin, Cam 5.2, AE/A13), neuroendocrine (neuron specific enolase, chromogranin A, and synaptophysin) and sarcoma (desmin, vimentin) markers.
  • The benign tumor was successfully managed conservatively with transurethral resection alone while for the malignant tumor, radical cystectomy, hysterectomy with bilateral salpingo-oophorectomy, anterior vaginectomy, plus lymph node dissection was done.
  • CONCLUSION: We recommend careful pathologic assessment for establishing the appropriate diagnosis and either a conservative or aggressive surgical treatment for benign or localized malignant GCT of the urinary bladder, respectively.
  • [MeSH-major] Cystoscopy / methods. Granular Cell Tumor / pathology. Granular Cell Tumor / surgery. Neoplasm Invasiveness / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Emergency Service, Hospital. Female. Follow-Up Studies. Hematuria / diagnosis. Hematuria / etiology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1973 Feb;109(2):101-11 [4124410.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1963 Oct;16:1202-13 [14079990.001]
  • [Cites] Br J Urol. 1961 Mar;33:76-9 [13683165.001]
  • [Cites] J Laryngol Otol. 1998 Apr;112(4):373-6 [9659502.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):48-58 [1985501.001]
  • [Cites] Br J Urol. 1985 Feb;57(1):109-10 [2982445.001]
  • [Cites] J Pathol. 1984 Mar;142(3):221-9 [6323661.001]
  • [Cites] Am J Pathol. 1983 Aug;112(2):139-46 [6192721.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1624-8 [6175391.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):239-48 [7189308.001]
  • [Cites] J Urol. 1974 Sep;112(3):343-5 [4368755.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:936-54 [13893237.001]
  • [Cites] Am J Clin Pathol. 1971 Dec;56(6):736-49 [4108241.001]
  • [Cites] Cancer. 1971 Apr;27(4):948-55 [4102365.001]
  • [Cites] Hinyokika Kiyo. 1969 Jul;15(7):505-13 [4310526.001]
  • [Cites] J Urol. 1968 Dec;100(6):735-7 [4301412.001]
  • [Cites] Int J Urol. 2001 Jan;8(1):29-31 [11168695.001]
  • [Cites] BJU Int. 1999 Nov;84(7):871-2 [10532990.001]
  • (PMID = 17355632.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1828733
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


59. Greiner B, Schulz C, Pfeifer M, Heiss P, Völk M, Feuerbach S, Hamer OW: [A 74-year-old female patient with histologically proven carcinoid of the lungs and pulmonary mosaic pattern]. Radiologe; 2009 Jun;49(6):538-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH) can be idiopathic or reactive to chronic airway disease, then termed pulmonary neuroendocrine cell hyperplasia (PNECH).
  • DIPNECH can be complicated by obliterative bronchiolitis and is presumably often misdiagnosed because the clinical symptoms are unspecific, the entity is relatively unknown and high-resolution computed tomography (HRCT) in inspiration and expiration is necessary for the diagnosis.
  • DIPNECH is thought to be a precursor of tumorlets and carcinoids and usually runs a benign course.
  • The diagnosis is confirmed by histology.
  • [MeSH-major] Carcinoid Tumor / diagnostic imaging. Carcinoid Tumor / pathology. Lung / diagnostic imaging. Lung / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Radiography

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2007 Mar;62(3):248-52 [17099078.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):839-44 [16784983.001]
  • [Cites] Am Rev Respir Dis. 1993 Nov;148(5):1166-8 [8239148.001]
  • [Cites] Chest. 2007 Jun;131(6):1635-43 [17400673.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):180-4 [11884770.001]
  • [Cites] Radiographics. 1999 May-Jun;19(3):707-36 [10336200.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):653-8 [7755151.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1561-2 [9168724.001]
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1285-8 [1406819.001]
  • (PMID = 19034406.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Louiset E, Isvi K, Gasc JM, Duparc C, Cauliez B, Laquerrière A, Kuhn JM, Lefebvre H: Ectopic expression of serotonin7 receptors in an adrenocortical carcinoma co-secreting renin and cortisol. Endocr Relat Cancer; 2008 Dec;15(4):1025-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abnormal expression of membrane receptors has been previously described in benign adrenocortical neoplasms causing Cushing's syndrome.
  • Tumor explants were obtained at surgery and processed for immunohistochemistry, in situ hybridization and cell culture studies.
  • In addition, immunohistochemistry showed the occurrence of 5-HT(7) receptor-like immunoreactivity in carcinoma cells. mRNAs encoding renin as well as renin-like immunoreactivity were detected in endothelial and tumor cells.
  • Cell incubation studies revealed that the adrenocortical tissue also released renin.
  • Our results also indicate that 5-HT can influence the secretory activity of malignant adrenocortical tumors in an autocrine/paracrine manner.
  • The effects of 5-HT on adrenocortical tumor cells included a paradoxical inhibitory action on renin production and a stimulatory action on cortisol secretion involving 5-HT(7) receptors.
  • [MeSH-minor] Adrenocorticotropic Hormone / pharmacology. Angiotensin II / pharmacology. Cushing Syndrome / metabolism. Cushing Syndrome / pathology. Female. Hormones / pharmacology. Humans. Immunoenzyme Techniques. In Situ Hybridization. Mast Cells / drug effects. Mast Cells / metabolism. Middle Aged. Phenols / pharmacology. Serotonin / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured / drug effects. Vasoconstrictor Agents / pharmacology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708508.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones; 0 / Phenols; 0 / Receptors, Serotonin; 0 / SB 269970; 0 / Sulfonamides; 0 / Vasoconstrictor Agents; 0 / serotonin 7 receptor; 11128-99-7 / Angiotensin II; 333DO1RDJY / Serotonin; 9002-60-2 / Adrenocorticotropic Hormone; EC 3.4.23.15 / Renin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


61. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Little is known about the immunohistochemical expression of cytokeratins 7 (CK7) and 20 (CK20) in appendiceal neuroendocrine tumors.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] World J Surg Oncol. 2005 Jun 20;3:36 [15967038.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38 [16253897.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Histopathology. 1992 Apr;20(4):345-9 [1577412.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):370-6 [16485156.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Ann Anat Pathol (Paris). 1969 Oct-Dec;14(4):393-406 [5378353.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):271-6 [15551743.001]
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


62. Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, Solis DC, Perera SM, Huynh TT, Lubensky IA, Tischler AS, Kvetnansky R, Alesci S, Morris JC, Pacak K: Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis; 2009;26(3):239-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytomas are chromaffin cell-derived neuroendocrine tumors.
  • There is presently no cure for metastatic pheochromocytoma and no reliable way to distinguish malignant from benign tumors before the development of metastases.
  • In order to successfully manage pheochromocytoma, it is necessary to better understand the biological determinants of tumor behavior.
  • We optimized this model modifying the number of cells injected, length of trypsin pre-treatment, and incubation temperature and duration for the MPC cells before injection, and by serial passage and re-selection of tumors exhibiting the metastatic phenotype.
  • We evaluated the effect of these modifications on tumor growth using serial in vivo Magnetic Resonance Imaging studies.
  • These results show that number of cells injected, the pre-injection incubation temperature, and duration of trypsin treatment are important factors to produce faster growing, more aggressive tumors that yielded secondary metastatic lesions.
  • Microarray gene expression comparison and quantitative real-time PCR of these more aggressive cells to the MPC-parental cell line identified genes that may be important for the metastatic process.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):139-43 [15523699.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:541-56 [17102123.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3900-7 [17525127.001]
  • [Cites] J Neurosci Methods. 2007 Sep 15;165(1):111-21 [17604116.001]
  • [Cites] Neuroimmunomodulation. 2007;14(5):221-3 [18219224.001]
  • [Cites] Mol Carcinog. 2008 Apr;47(4):245-51 [17957724.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12337-42 [18719100.001]
  • [Cites] J Magn Reson Imaging. 2009 Mar;29(3):685-91 [19243052.001]
  • [Cites] Cell Tissue Res. 2000 Dec;302(3):309-20 [11151443.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1999-2008 [11344198.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):883-95 [15168351.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Cell Tissue Res. 1983;228(3):641-8 [6682015.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:392-404 [17102108.001]
  • (PMID = 19169894.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIC HG200365-03; United States / Intramural NIH HHS / / ZIC HG200365-01; United States / NINDS NIH HHS / NS / R01 NS037685; United States / NINDS NIH HHS / NS / NS 37685; United States / Intramural NIH HHS / / ZIC HG200365-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS420223; NLM/ PMC3505859
  •  go-up   go-down


63. Howman-Giles R, Shaw PJ, Uren RF, Chung DK: Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med; 2007 Jul;37(4):286-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma and other neuroendocrine tumors.
  • Neuroblastoma is the most common extracranial solid tumor of childhood.
  • There is marked variability in clinical behavior ranging from spontaneous regression or differentiation into benign tumors to rapid and progressive fatal disease.
  • Whole body imaging with (123)I-MIBG has become the preferred diagnostic test because this agent accumulates in neuroblastoma in 90% to 95% of cases and will accumulate in the primary tumor and metastases particularly in bone, bone marrow, lymph nodes, and soft tissues.
  • Neuroendocrine tumors (NETs) are rare in childhood, but nuclear medicine techniques, mainly using MIBG and somatostatin receptor agents, have a role in diagnosis, staging, and a limited role in therapy.
  • [MeSH-major] Neuroblastoma / radionuclide imaging. Neuroendocrine Tumors / radionuclide imaging

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544628.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


64. Mazurkiewicz M, Wasiutyński A: [Current opinion in pathogenesis of pheochromocytoma]. Pol Merkur Lekarski; 2007 Jun;22(132):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pheochromocytoma is a neuroendocrine tumor with significant clinical relevance.
  • Most of the tumors are benign, but sometimes malignant cases are seen and there prognosis is unfavorable.

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874618.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] Poland
  •  go-up   go-down


65. Unal M, Polat A, Pata YS, Vayisoğlu Y, Yildiz A, Ismi O: Paraganglioma of the skull base: a case report. Auris Nasus Larynx; 2007 Sep;34(3):427-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraganglioma of the skull base: a case report.
  • Paragangliomas are rare benign neuroendocrine tumors derived from the extra-adrenal paraganglia of the autonomic nervous system.
  • Here, we described a new case of a 75-year-old woman with paraganglioma arising in the middle and posterior cranial fossa with extended destruction of the skull base and clivus.
  • [MeSH-major] Paraganglioma / diagnosis. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy. Chromogranin A / analysis. Endoscopy. Female. Humans. Magnetic Resonance Imaging. Respiratory Insufficiency / etiology. S100 Proteins / analysis. Skull Base / pathology. Synaptophysin / analysis. Tomography, X-Ray Computed. Vocal Cord Paralysis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331688.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / S100 Proteins; 0 / Synaptophysin
  •  go-up   go-down


66. Magri K, Demoulin G, Millon G, Duvert B: [Metastasis to the breast from non mammary metastasis. Clinical, radiological characteristics and diagnostic process. A report of two cases and a review of literature]. J Gynecol Obstet Biol Reprod (Paris); 2007 Oct;36(6):602-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasis to the breast from non mammary metastasis. Clinical, radiological characteristics and diagnostic process. A report of two cases and a review of literature].
  • All cancers can give breast metastases, several months after the discovery of the primitive tumor or in 25% of the cases in being the first sign.
  • Their clinical and radiological presentation polymorphic installation a problem of differential diagnosis between benign tumor, like the fibroadenomas on the one hand, and malignant tumors of other share.
  • The presence of multiple, bilateral round tumors, superficial without the traditional signs of malignity which one meets with the primitive tumors: irregular margins, spiculations, microcalcifications, posterior cone of shadow is evocative diagnosis.
  • The IRM finds the criteria of malignity specific to the primitive tumor.
  • Pathologic examination completed with immunohistochemical tests is a key point for diagnosis.
  • The search for a primitive tumor is essential, in particular for neuroendocrine carcinoma, stromal sarcoma, and the angiosarcoma which can be primitive tumors of the breast.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Female. Humans. Immunohistochemistry. Lung Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Melanoma / diagnosis. Middle Aged. Radiotherapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590284.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


67. Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M: Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol; 2010 Mar;21(3):548-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.
  • BACKGROUND: The management of pulmonary neuroendocrine tumours (NETs), with special reference to clinically aggressive carcinoids and large-cell neuroendocrine carcinomas (LCNECs), is poorly standardised and data about somatostatin receptor (SSTR) expression or therapeutic guidelines for somatostatin analogue administration are still debated.
  • MATERIALS AND METHODS: A series of 218 lung NETs [24 metastatic typical carcinoids (TCs), 73 atypical carcinoids (ACs), 60 LCNECs and 61 surgically resected small-cell lung carcinomas] were investigated for SSTR types 2A and 3 tissue distribution using immunohistochemistry, in correlation with clinicopathologic parameters, outcome, scintigraphy and treatment.
  • SSTR type 2A was strikingly overexpressed in metastatic TCs as compared with ACs and clinically benign TCs.
  • CONCLUSION: The immunohistochemical determination of SSTRs, with special reference to low-grade/intermediate-grade tumours, may assist the clinical approach with somatostatin analogue-based diagnostic and therapeutic procedures in clinically aggressive pulmonary NETs.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19759190.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 3
  •  go-up   go-down


68. Poves I, Burdío F, Iglesias M, Martínez-Serrano Mde L, Aguilar G, Grande L: Resection of the uncinate process of the pancreas due to a ganglioneuroma. World J Gastroenterol; 2009 Sep 14;15(34):4334-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Findings were suggestive of a mucinous or solid-cystic pseudopapillary tumor of the pancreas, although other lesions such as a non-functioning neuroendocrine tumor could not be ruled out.
  • It was decided to surgically remove the tumor because malignancy could not be discounted.
  • Multiple intraoperative biopsies were suggestive of mesenchymal tumor and consequently a conservative resection (uncinatectomy) was performed.
  • The definitive diagnosis was ganglioneuroma.
  • Ganglioneuroma is a rare benign tumor that can also present as a pancreatic tumor.
  • Uncinatectomy is feasible, safe and a good surgical technique for the treatment of non-malignant tumors located in the uncinate process of the pancreas.
  • [MeSH-major] Ganglioneuroma / diagnosis. Ganglioneuroma / surgery. Pancreas / surgery. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S51-61 [11762353.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):66-74 [11986020.001]
  • [Cites] Radiographics. 2002 Jul-Aug;22(4):911-34 [12110723.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1607-21; discussion 1621-2 [17896167.001]
  • [Cites] Diagn Cytopathol. 1999 Sep;21(3):194-6 [10450105.001]
  • [Cites] Diagn Cytopathol. 2005 Jun;32(6):363-6 [15880712.001]
  • [Cites] Dig Surg. 2006;23(1-2):121-4 [16804308.001]
  • [Cites] Cir Esp. 2007 Aug;82(2):105-11 [17785144.001]
  • [Cites] Diagn Cytopathol. 1998 Nov;19(5):385-7 [9812237.001]
  • (PMID = 19750580.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2744193
  •  go-up   go-down


69. Capolunghi B, Bertolini G, Grillo della Berta L, Tinelli N, Cascio F, Bertoletti F: Laryngeal paraganglioma: an endoscopic diode-laser-assisted surgical approach: a case report. B-ENT; 2005;1(2):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal paraganglioma: an endoscopic diode-laser-assisted surgical approach: a case report.
  • Laryngeal paraganglioma is a rare vascular neuroendocrine benign tumour.
  • Computed tomography scans and angiography are also useful in making the diagnosis of paraganglioma before surgical intervention.
  • A case of a large supraglottic paraganglioma is described.
  • Complete excision of the tumour was achieved using microlaryngoscopical-laser surgical resection.
  • The effectiveness of this conservative endoscopic surgical procedure compared to the external approaches is discussed and it can be concluded that the endoscopic diode-laser resection of even extended laryngeal paraganglioma provides a good operative field and is a safe and effective technique.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laser Therapy / methods. Paraganglioma / surgery

  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044742.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


70. Sarma DP, Heagley DE, Chalupa J, Cox M, Shehan JM: An unusual clinical presentation of merkel cell carcinoma: a case report. Case Rep Med; 2010;2010:905414
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual clinical presentation of merkel cell carcinoma: a case report.
  • Introduction. Merkel cell carcinoma is a rare, aggressive neuroendocrine cell carcinoma arising in the sun-exposed skin of elderly patients.
  • Most of these tumors are located in the dermis.
  • An unusual clinical presentation of such a tumor in the subcutis, if not biopsied, may be easily mistaken as a benign lesion.
  • At the insistence of the patient, an excisional biopsy of the mass was performed revealing a subcutaneous Merkel cell carcinoma.
  • The tumor cells stained positively for CK 20, chromogranin, and synaptophysin.
  • No other primary or metastatic tumors found after a thorough work-up.
  • Conclusion. When a new growth is encountered in the sun-exposed skin of elderly patients, a biopsy is warranted even if the lesion clinically appears benign.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Pathol. 2009 Dec;36(12):1327-9 [19878388.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):4021-6 [19597021.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):717-9 [15996429.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):51-6 [17270666.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):375-81 [18280333.001]
  • (PMID = 20300432.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2840409
  •  go-up   go-down


71. Farnedi A, Eusebi LH, Poli F, Foschini MP: Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions. Int J Surg Pathol; 2009 Aug;17(4):327-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions.
  • MATERIALS AND METHODS: Seventy-seven samples were stained immunohistochemically with a monoclonal antibody for hNIS, including 14 with normal gastric mucosa, 14 with chronic atrophic gastritis with foveolar hyperplasia, 15 with chronic atrophic gastritis with intestinal metaplasia, 6 with chronic atrophic gastritis with atypical regenerative hyperplasia, 8 with chronic atrophic gastritis with dysplasia, 15 with invasive adenocarcinoma, 3 with well-differentiated neuroendocrine tumor, and 2 with gastrointestinal stromal tumors (GISTs).
  • RESULTS: hNIS stained the basolateral cytoplasmic portion of foveolae in normal mucosa, in 13 cases of chronic atrophic gastritis with foveolar hyperplasia, and in only 1 case of regenerative atypical hyperplasia. hNIS was consistently absent in intestinal metaplasia, in dysplastic glands, and in the cells constituting invasive carcinoma, well-differentiated neuroendocrine tumors, and GIST.
  • [MeSH-major] Gastritis, Atrophic / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Neuroendocrine Tumors / diagnosis. Precancerous Conditions / pathology. Stomach Neoplasms / diagnosis. Symporters / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Chronic Disease. Diagnosis, Differential. Female. Gastric Mucosa / metabolism. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Male. Metaplasia / diagnosis. Metaplasia / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19124451.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Symporters; 0 / sodium-iodide symporter
  •  go-up   go-down


72. Guérin M, Guillemot J, Thouënnon E, Pierre A, El-Yamani FZ, Montero-Hadjadje M, Dubessy C, Magoul R, Lihrmann I, Anouar Y, Yon L: Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept; 2010 Nov 30;165(1):21-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma.
  • Pheochromocytomas are rare catecholamine-secreting tumors that arise from chromaffin tissue within the adrenal medulla and extra-adrenal sites.
  • The diagnosis of pheochromocytomas depends mainly upon the demonstration of catecholamine excess by 24-h urinary catecholamines and metanephrines or plasma metanephrines.
  • The characterization of tissue, circulating or genetic markers is therefore crucial for the management of these tumors.
  • Proteins of the granin family and their derived peptides are present in dense-core secretory vesicles and secreted into the bloodstream, making them useful markers for the identification of neuroendocrine cells and neoplasms.
  • In this context, we will focus here on reviewing the distribution and characterization of granins and their processing products in normal and tumoral chromaffin cells, and their clinical usefulness for the diagnosis and prognosis of pheochromocytomas.
  • In most cases, elevated levels of these entities were found, in correlation with tumor occurrence, while rarely discriminating between benign and malignant neoplasms.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / pathology. Chromaffin Cells / metabolism. Chromaffin Cells / pathology. Chromogranins / metabolism. Pheochromocytoma / diagnosis. Pheochromocytoma / pathology


73. Shah GV, Muralidharan A, Gokulgandhi M, Soan K, Thomas S: Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer. J Biol Chem; 2009 Jan 9;284(2):1018-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcitonin, a neuroendocrine peptide, and its receptor are localized in the basal epithelium of benign prostate but in the secretory epithelium of malignant prostates.
  • Moreover, calcitonin increases tumorigenicity and invasiveness of multiple prostate cancer cell lines by cyclic AMP-dependent protein kinase-mediated actions.
  • These actions include increased secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in prostate cancer cell invasion.
  • Activation of calcitonin-calcitonin receptor autocrine loop in prostate cancer cell lines led to the loss of cell-cell adhesion, destabilization of tight and adherens junctions, and internalization of key integral membrane proteins.
  • These results for the first time identify actions of calcitonin-calcitonin receptor axis on prostate cancer cells that lead to the destabilization of cell-cell junctions, epithelial-to-mesenchymal transition, and activation of WNT/beta-catenin signaling.
  • The results also suggest that cyclic AMP-dependent protein kinase plays a key role in calcitonin receptor-induced destabilization of cell-cell junctions and activation of WNT-beta-catenin signaling.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):337-41 [12432242.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11960-5 [11035810.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1959-67 [12668723.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2672-2680 [14755243.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):511-21 [15327768.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Aug;79(15):4672-6 [6956885.001]
  • [Cites] Ciba Found Symp. 1988;141:48-74 [3075937.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Prostate. 1993;22(2):109-18 [7681204.001]
  • [Cites] Urol Res. 1993;21(5):359-62 [7506464.001]
  • [Cites] Endocrinology. 1994 Feb;134(2):596-602 [8299557.001]
  • [Cites] J Postgrad Med. 1993 Oct-Dec;39(4):197-201 [7996496.001]
  • [Cites] Mol Endocrinol. 1995 Aug;9(8):959-68 [7476993.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):46-54 [11149419.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • [Cites] Pathol Int. 2001 Jun;51(6):452-9 [11422807.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jul 5;181(1-2):69-79 [11476942.001]
  • [Cites] Cell Growth Differ. 2001 Dec;12(12):631-40 [11751458.001]
  • [Cites] J Cell Sci. 2002 Nov 15;115(Pt 22):4227-36 [12376555.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):301-14 [12398894.001]
  • [Cites] Histol Histopathol. 2005 Jan;20(1):197-203 [15578438.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):873-87 [15713751.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4591-601 [15899862.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8519-29 [16166333.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):551-60 [15929083.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):9063-72 [16199882.001]
  • [Cites] Urol Oncol. 2005 Nov-Dec;23(6):402-6 [16301117.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):6566-78 [16314317.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11649-57 [16357176.001]
  • [Cites] Cancer Biol Ther. 2005 Nov;4(11):1226-33 [16222118.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):131-40 [16520277.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2694-702 [16381004.001]
  • [Cites] Mol Endocrinol. 2006 Aug;20(8):1894-911 [16574742.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1664-73 [16902972.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4042-5 [17634527.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] J Surg Oncol. 2007 Oct 1;96(5):419-23 [17874463.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):27-58 [17939294.001]
  • [Cites] Int J Oncol. 2007 Dec;31(6):1425-37 [17982669.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7003-11 [18056176.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):559-71 [18068632.001]
  • [Cites] J Cell Biochem. 2008 May 1;104(1):304-17 [17990294.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):319-25 [18536569.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):137-42 [12545177.001]
  • [Cites] Am J Physiol. 1995 Oct;269(4 Pt 1):G467-75 [7485497.001]
  • [Cites] Urology. 1996 Mar;47(3):376-81 [8633405.001]
  • [Cites] Cell Struct Funct. 1996 Oct;21(5):381-5 [9118244.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1393-401 [9182670.001]
  • [Cites] Mol Pathol. 1997 Dec;50(6):289-90 [9536277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Oncogene. 1999 Jun 3;18(22):3376-82 [10362358.001]
  • [Cites] Int J Urol. 1999 May;6(5):240-4 [10375186.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24579-84 [10455122.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2717-25 [15571953.001]
  • [Cites] Radiol Clin North Am. 2000 Jan;38(1):49-58 [10664666.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1671-6 [10749138.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4135-40 [18647815.001]
  • (PMID = 19001380.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / Receptors, Calcitonin; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein; 0 / beta Catenin; 9007-12-9 / Calcitonin; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC2613615
  •  go-up   go-down


74. Schlottmann K: [Reader's letter concerning the article by H. Strunk et al. (Fortschr Röntgenstr 2005, 177:900-904). Erroneous diagnosis of liver metastasis as benign tumor in the contrast media aided "Low-MI-Real-Time" sonography with SonoVue]. Rofo; 2005 Dec;177(12):1722-3; author reply 1723
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reader's letter concerning the article by H. Strunk et al. (Fortschr Röntgenstr 2005, 177:900-904). Erroneous diagnosis of liver metastasis as benign tumor in the contrast media aided "Low-MI-Real-Time" sonography with SonoVue].
  • [Transliterated title] Leserbrief zum Beitrag H. Strunk et al. (Fortschr Röntgenstr 2005; 177: 900-904). Fehldiagnose einer Lebermetastase als benigner Tumor in der kontrastmittelgestützten "Low-MI-Real-Time"--Sonographie mit SonoVue.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Carcinoma, Neuroendocrine / ultrasonography. Liver Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride
  • [MeSH-minor] Diagnosis, Differential. Humans. Time Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Rofo. 2005 Jun;177(6):900-2 [15902642.001]
  • (PMID = 16382508.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comment; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


75. Angouridakis N, Hytiroglou P, Markou K, Bouzakis A, Vital V: Middle ear adenoma/carcinoid tumour: a case report and review of the literature. Rev Laryngol Otol Rhinol (Bord); 2009;130(3):199-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Middle ear adenoma/carcinoid tumour: a case report and review of the literature.
  • Middle ear adenoma, a rare benign tumour with glandular and neuroendocrine differentiation, originates from the epithelial lining of the middle ear.
  • Histological examination revealed tumour cells forming gland-like and cribriform structures, as well as compact groups.
  • On immunohistochemical staining, the tumour cells were positive for epithelial (cytokeratins, epithelial membrane antigen) and neuroendocrine (neuron specific enolase, synaptophysin, chromogranin and pancreatic polypeptide) markers.
  • CONCLUSION: Middle ear adenoma is a benign tumour that is treated by complete surgical removal.
  • The immunohistochemical staining of the present case supports the suggestion that this tumour is best described by the term neuroendocrine adenoma of the middle ear.
  • [MeSH-major] Adenoma. Carcinoid Tumor. Ear Neoplasms. Ear, Middle

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for middle ear adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20345079.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


76. Das-Neves-Pereira JC, de Matos LL, Danel C, Trufelli D, Riquet M: Typical bronchopulmonary carcinoid tumors: a ramifying bronchial presentation with metastatic behavior. Ann Thorac Surg; 2006 Dec;82(6):2265-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Typical bronchopulmonary carcinoid tumors: a ramifying bronchial presentation with metastatic behavior.
  • Bronchopulmonary typical carcinoid tumors (BTCT) are neuroendocrine neoplasms with histologic low grade characteristics considered benign.
  • Metastasis occurred despite typical carcinoid microscopic features in 3 female patients of African origin presenting at macroscopic examination as ramifying bronchopulmonary typical carcinoid tumors following the bronchial tree.
  • We suggest that clinical ramifying presentation may be related to metastatic behavior, even for bronchopulmonary typical carcinoid tumors not displaying histologic criteria for atypical carcinoid tumors.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126146.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Somogyi A, Ruzicska E, Varga T, Rácz K, Nagy G: [Development of silent gastric carcinoid in a type 1 diabetic patient with primer hypothyreosis]. Orv Hetil; 2007 Sep 2;148(35):1667-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parietal cell antibodies (PCA) are found in 20% of type 1 diabetic patients which might be an early sign of autoimmune gastritis and pernicious anemia.
  • ECL hyper/dysplasia is known to increase the likelihood of gastric carcinoid tumor development in affected patients.
  • Gastric carcinoid tumors forming from the hyperplasia of ECL cells are found in 4-9% of patients having autoimmune gastritis or pernicious anemia.
  • The parietal cell antibody test was positive, the serum chromogranin A level was 289,7 ng/ml (normal value $ 98 ng/ml), TSH level was 9,93 mIU/L.
  • The histological examination indicated carcinoid tumor.
  • Non-antral, multiple polyps could cover silent neuroendocrine tumors, which are slowly growing benign endocrine tumors, however, they also might be high malignity endocrine carcinomas.
  • These tumors could be easily recognized in the clinical practice by measuring the serum or tissue chromogranin A level and other markers of tumor growth.
  • Thus screening of gastric endocrine tumors in type 1 diabetic patients with co-morbid autoimmune diseases is recommended.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoid Tumor / diagnosis. Chromogranin A / blood. Diabetes Complications / diagnosis. Diabetes Mellitus, Type 1 / complications. Hypothyroidism / complications. Stomach Neoplasms / diagnosis


78. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • Endocrine tumors (ET) of the digestive tract (formerly called neuroendocrine tumors) are rare.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • The surgical goals are to: 1. prolong survival by resecting the primary tumor and any nodal or hepatic metastases, 2. control the symptoms related to hormonal secretion, 3. prevent or treat local complications.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • For gastrinoma with NEM-I, the benefit of surgical resection for tumors less than 2-3 cm in size is not clear.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


79. Monsef N, Helczynski L, Lundwall A, Påhlman S, Anders-Bjartell: Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands. Prostate; 2007 Aug 1;67(11):1219-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
  • BACKGROUND: Hypoxia induces increased tumor growth by promoting angiogenic and glycolytic pathways.
  • Tumors expressing hypoxia-inducible factor-1alpha (HIF-1alpha), an important transcriptional activator of oxygen-regulated genes, are resistant to chemotherapy and radiotherapy.
  • The major challenge in prostate cancer therapy today is to gain a better understanding of the development of hormone-refractory tumors, which is often characterized by neuroendocrine differentiation.
  • Here we studied the expression of HIF-1alpha and HIF-2alpha in neuroendocrine cells of the benign prostate and in prostate cancer.
  • METHODS: Tissue sections from 30 patients who underwent radical prostatectomy and from 21 patients operated by transurethral resection of the prostate were selected for immunohistochemical analysis for expression of HIF-1alpha, HIF-2alpha, androgen receptor (AR), neuroendocrine markers (chromogranin A, synaptophysin), and two gene products downstream of HIF-1alpha: VEGF and GAPDH.
  • RESULTS: Immunoreactive HIF-1alpha was detected in a subpopulation of AR-negative neuroendocrine cells in benign and malignant prostate tissue.
  • Analysis of serial sections showed that the levels of expression of GAPDH and VEGF proteins are increased in AR-negative malignant neuroendocrine cells expressing HIF-1alpha.
  • In situ-hybridization indicated that HIF-1alpha mRNA levels are not higher in neuroendocrine prostate cancer cells relative to corresponding non-neuroendocrine tumor cells.
  • Focal HIF-2 expression was detected in benign neuroendocrine-like cells and in malignant prostatic cells.
  • CONCLUSIONS: The expression of HIF-1alpha and HIF-2alpha in prostate cancer has been confirmed, but we also identified immunoreactive HIF-1alpha and downstream gene products in benign and malignant prostate neuroendocrine cells.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Prostatectomy. RNA, Messenger / analysis. Receptors, Androgen / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17562539.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / endothelial PAS domain-containing protein 1
  •  go-up   go-down


81. Teh SH, Tseng D, Sheppard BC: Laparoscopic and open distal pancreatic resection for benign pancreatic disease. J Gastrointest Surg; 2007 Sep;11(9):1120-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic and open distal pancreatic resection for benign pancreatic disease.
  • The aim of the study is to provide comparisons of the perioperative outcomes between open and laparoscopic distal pancreatic resection (DPR) for benign pancreatic disease.
  • From 2002 and 2005, there were 28 patients (16 open, 12 laparoscopic) with a mean age of 52 who had presumptive diagnoses of benign pancreatic lesions.
  • Pathology was neuroendocrine tumor (nine and five), mucinous cystic neoplasm (three and three), symptomatic pancreatic pseudocyst (two and two), and others (two and two).
  • Laparoscopic DPR is technically feasible, safe, and associated with less perioperative morbidity and a shorter hospital stay than open DPR.
  • In centers with the appropriate expertise, laparoscopic DPR should be considered the procedure of choice for putative benign lesions of the pancreatic body and tail.

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Surg Clin North Am. 2000 Aug;80(4):1151-70 [10987029.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2004 Aug;14(4):181-5 [15472543.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):208-12; discussion 212-3 [7840381.001]
  • [Cites] Transplantation. 1997 Jan 27;63(2):229-33 [9020322.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Br J Surg. 1999 May;86(5):608-11 [10361178.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):156-64 [7857143.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):996-1003 [12163971.001]
  • [Cites] Cancer J. 2005 Jan-Feb;11(1):43-51 [15831223.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):280-5 [8604908.001]
  • [Cites] Ann Surg. 2005 Jun;241(6):919-26; discussion 926-8 [15912041.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):249-53 [11314942.001]
  • [Cites] World J Surg. 1998 May;22(5):494-8 [9564295.001]
  • [Cites] Surgery. 2003 Jul;134(1):45-52 [12874582.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):149-58 [12170019.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):620-4 [15816491.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1057-65 [12016486.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):190-6 [12555295.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):975-82 [15286957.001]
  • [Cites] Surg Endosc. 2005 Aug;19(8):1028-34 [16027987.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):493-501 [15120376.001]
  • (PMID = 17623260.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Tambo M, Fujimoto K, Miyake M, Hoshiyama F, Matsushita C, Hirao Y: Clinicopathological review of 46 primary retroperitoneal tumors. Int J Urol; 2007 Sep;14(9):785-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological review of 46 primary retroperitoneal tumors.
  • OBJECTIVES: To clarify the clinical factors including diagnostic imaging findings that may correlate with the histopathological malignancy in primary retroperitoneal tumors.
  • METHODS: The clinical backgrounds and imaging findings of 22 benign and 24 malignant primary retroperitoneal tumors were retrospectively investigated, and the prognosis of patients with malignant retroperitoneal tumors was assessed.
  • RESULTS: There were significant correlations between the presence of symptoms and malignancy (P < 0.01), as well as between the irregularity of tumor margins and malignancy (P < 0.01).
  • On dynamic magnetic resonance imaging (MRI), 90% of malignant tumors showed early enhancement either with quick or slow washout, while 75% of benign tumors showed delayed and no enhancement (P < 0.002).
  • All malignant and benign paraganglioma showed the same early enhancement with quick washout.
  • The 2-year and 5-year cause-specific survival rates of the patients with malignant retroperitoneal tumors were 68.0% and 43.2%, respectively.
  • Malignant paraganglioma patients who could not meet complete resection needed chemotherapy for promising survival.
  • CONCLUSION: The symptoms, the irregularity of the margins, and the specific enhancement pattern on the dynamic MRI may be important predictive factors of the primary malignant retroperitoneal tumors.
  • Histological diagnosis was needed for malignant definition of paraganglioma because both benign and malignant paraganglioma showed similar clinical and imaging findings.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retroperitoneal Space / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760742.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


83. Iglesias-Garcia J, Larino-Noia J, Abdulkader I, Forteza J, Dominguez-Munoz JE: Quantitative endoscopic ultrasound elastography: an accurate method for the differentiation of solid pancreatic masses. Gastroenterology; 2010 Oct;139(4):1172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Qualitative endoscopic ultrasound (EUS) elastography is an accurate but subjective tool for the differential diagnosis of solid pancreatic masses.
  • We evaluated the accuracy of quantitative, second-generation EUS elastography in the differential diagnosis of solid pancreatic masses.
  • Final diagnosis was based on histology of surgical specimens and cytology of EUS-fine-needle aspiration samples.
  • The final diagnoses were pancreatic adenocarcinoma (n = 49), inflammatory mass (n = 27), malignant neuroendocrine tumor (n = 6), metastatic oat-cell lung cancer (n = 2), pancreatic lymphoma (n = 1), and pancreatic solid pseudopapillary tumor (n = 1).
  • The strain ratio was significantly higher among patients with pancreatic malignant tumors compared with those with inflammatory masses.
  • CONCLUSIONS: Quantitative, second-generation EUS elastography is useful for differential diagnosis of solid pancreatic masses.
  • It allows for a quantitative and objective evaluation of tissue stiffness, which indicates the malignant or benign nature of the pancreatic lesion.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20600020.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Ferlito A, Silver CE, Bradford CR, Rinaldo A: Neuroendocrine neoplasms of the larynx: an overview. Head Neck; 2009 Dec;31(12):1634-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine neoplasms of the larynx: an overview.
  • Neuroendocrine neoplasms of the larynx are rare but are the most common nonsquamous tumors of this organ.
  • In the past, there has been considerable confusion about the nature and classification of these neoplasms, but the current consensus is that there are 4 different types of laryngeal neuroendocrine tumors composed of paraganglioma, typical carcinoid, atypical carcinoid tumor, and small cell neuroendocrine carcinoma.
  • Carcinoids and small cell neuroendocrine carcinomas are epithelial neoplasms, whereas paragangliomas are of neural origin.
  • Diagnosis is based primarily on light microscopy and confirmed by immunohistochemistry and electron microscopy.
  • Precise diagnosis is essential because the natural history, treatment, and prognosis vary widely for the different neoplastic categories.
  • Atypical carcinoid tumors are more common and more aggressive.
  • Small cell neuroendocrine carcinomas are highly aggressive and should be considered disseminated at initial diagnosis.
  • Paragangliomas are treated by local excision or partial laryngectomy.
  • Atypical carcinoid tumors have a 5-year survival rate of approximately 50%, which decreases with time.
  • The prognosis of small cell neuroendocrine carcinoma of the larynx is dismal, with 5-year survival rates of 5%.
  • The biological behavior of laryngeal paraganglioma is generally benign and the prognosis is excellent.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Laryngectomy / methods. Male. Neck Dissection / methods. Neoplasm Staging. Paraganglioma / mortality. Paraganglioma / pathology. Paraganglioma / therapy. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536850.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 89
  •  go-up   go-down


85. Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Böhling T: Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol; 2005 Mar;58(3):297-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C in primary Merkel cell carcinoma.
  • BACKGROUND/AIMS: Merkel cell carcinoma (MCC) is a rare malignant cutaneous neuroendocrine tumour that mostly affects the elderly.
  • It shows rapid progression of the primary tumour, together with a vertical growth pattern into the underlying subcutaneous tissue.
  • Tenascin-C (Tn-C) is a large extracellular matrix glycoprotein that is expressed in various benign and malignant processes.
  • In previous studies, Tn-C expression correlated with prognosis in tumours of different origin.
  • Staining was mainly seen in the invasion borders and within the connective tissue septae inside the tumours.
  • The expression of Tn-C correlated significantly with large tumour size.
  • There was also frequent expression of Tn-C in primary tumours with metastatic dissemination.
  • CONCLUSIONS: Tn-C expression seems to increase with tumour size and malignant behaviour.
  • Expression was slightly enhanced in tumours with high proliferative indices.
  • Expression is seen mainly in areas of invasive growth and, in this respect, resembles that of other invasive tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Merkel Cell / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism. Tenascin / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Division. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jan;31(1):58-62 [10665914.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Forensic Sci Int. 2002 Apr 18;126(2):118-22 [12084487.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3051-6 [12926160.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):607-10 [12943628.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):31-40 [14618612.001]
  • [Cites] APMIS. 2004 Jan;112(1):39-44 [14961973.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4587-91 [14981900.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Sci Am. 1986 Jun;254(6):42-51 [3010451.001]
  • [Cites] Dev Biol. 1988 Aug;128(2):245-55 [2456233.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Br J Dermatol. 1991 Jan;124(1):13-20 [1704250.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):811-6 [1707033.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1143-50 [1719820.001]
  • [Cites] Invasion Metastasis. 1991;11(6):325-31 [1726610.001]
  • [Cites] Development. 1993 Apr;117(4):1183-98 [8404525.001]
  • [Cites] Perspect Dev Neurobiol. 1994;2(1):111-16 [7530137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23 [7836085.001]
  • [Cites] Methods Enzymol. 1994;245:52-61 [7539094.001]
  • [Cites] Int Arch Allergy Immunol. 1995 Aug;107(4):484-90 [7620364.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):445-7 [8980244.001]
  • [Cites] Matrix Biol. 1998 Aug;17(4):305-16 [9749946.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):1035-41 [9816077.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1687-92 [9893653.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):16-20 [10027519.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):415-21 [10366470.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • (PMID = 15735164.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1770604
  •  go-up   go-down


86. Valdes EK, Feldman SM, Krassilnik N: Neuroendocrine tumor of the breast. Am Surg; 2006 Feb;72(2):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumor of the breast.
  • Mammary carcinoid is an uncommon neoplasm.
  • It is well-known that neuroendocrine elements can be demonstrated in ductal and lobular carcinoma.
  • However, it is still controversial whether mammary carcinoid tumors should be considered a distinct clinical entity or be treated as a variant of conventional breast carcinoma.
  • Differentiating these lesions from benign lesions such as epithelial hyperplasia and papillomas can be challenging at times.
  • We present a case of neuroendocrine tumor of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoid Tumor / pathology. Carcinoma, Ductal, Breast / pathology


87. Mabrut JY, Boulez J, Peix JL, Gigot JF, Gouillat C, de La Roche E, Ducerf C, Baulieux J: Laparoscopic pancreatic resection: a preliminary experience of 15 patients. Hepatogastroenterology; 2005 Jan-Feb;52(61):230-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: 15 consecutive patients suffering from benign cystic pancreatic (n=6), neuroendocrine tumors (n=8) or pancreatic metastasis from renal carcinoma (n=1) undergoing laparoscopic pancreatic resection were retrospectively collected from 5 academic hospitals.
  • RESULTS: Laparoscopic procedure was completed in 10 patients, including 7 distal pancreatectomies (with 5 spleen preservation), 2 tumor enucleations and 1 partial cystic resection.
  • CONCLUSIONS: Laparoscopic pancreatic resection is feasible for distal pancreatic tumors.
  • [MeSH-major] Cystadenoma / surgery. Laparoscopy. Neuroendocrine Tumors / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783037.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Hopt U, Keck T: [Pancreatic incidentalomas. Correct assessment and therapy]. Chirurg; 2007 Aug;78(8):713-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic incidentalomas should be differentiated into solid and cystic tumors.
  • In both subgroups definitive classification of the tumor is often not possible.
  • In case of cystic incidentalomas, benign cystic lesions should be excluded as far as possible.
  • In case of IPMN with specific risk factors, resection is recommended when the tumor size exceeds 1 cm.
  • [MeSH-major] Incidental Findings. Pancreatic Diseases / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Diagnosis, Differential. Diagnostic Imaging. Humans. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreas / pathology. Pancreatectomy. Pancreatitis, Chronic / diagnosis. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / surgery. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] Pancreas. 2006 Apr;32(3):276-80 [16628083.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):532-9 [10228857.001]
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9 [15623441.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1485-7 [9609158.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):59-64 [12838222.001]
  • [Cites] World J Surg. 2003 Nov;27(11):1249-57 [14502404.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):383-9 [16111956.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):909-18 [10816635.001]
  • [Cites] Semin Diagn Pathol. 2004 Nov;21(4):260-7 [16273945.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Jul;15(3):497-510 [16882494.001]
  • [Cites] JOP. 2006 May 09;7(3):262-73 [16685107.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):367-71 [10968852.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):201-8 [14769305.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):20-3 [15615944.001]
  • [Cites] Int J Gastrointest Cancer. 2001;30(1-2):27-31 [12489578.001]
  • [Cites] Dig Dis. 2004;22(1):6-17 [15292690.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Endocrinol Metab Clin North Am. 2006 Jun;35(2):431-47, xii [16632104.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):728-36; quiz 751, 753 [16246688.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):611-8; discussion 618-9 [1357827.001]
  • [Cites] Semin Diagn Pathol. 2005 Nov;22(4):309-17 [16939059.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] Chirurg. 2004 Nov;75(11):1079-87 [15448934.001]
  • [Cites] Langenbecks Arch Surg. 2002 Mar;386(8):558-69 [11914931.001]
  • [Cites] Surgery. 1996 Dec;120(6):975-83; discussion 983-4 [8957483.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):155-78 [16517154.001]
  • [Cites] Int J Pancreatol. 1996 Apr;19(2):145-53 [8723558.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):738-44 [11297271.001]
  • [Cites] Am Surg. 2000 Dec;66(12):1116-22; discussion 1122-3 [11149582.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Hepatogastroenterology. 2000 Nov-Dec;47(36):1750-2 [11149048.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Pancreas. 1998 Apr;16(3):396-401 [9548685.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):610-6 [16163029.001]
  • [Cites] Cancer Treat Rev. 2005 Nov;31(7):507-35 [16257126.001]
  • [Cites] J Comput Assist Tomogr. 1999 Nov-Dec;23 (6):906-12 [10589565.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Pancreas. 2006 Oct;33(3):211-20 [17003640.001]
  • (PMID = 17628760.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Singh N, Lo CY, Chan WF: Laparoscopic enucleation of a nonfunctioning neuroendocrine tumor at the head of the pancreas. JSLS; 2006 Apr-Jun;10(2):259-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic enucleation of a nonfunctioning neuroendocrine tumor at the head of the pancreas.
  • OBJECTIVE: Laparoscopy is a safe, feasible technique for benign pancreatic pathologies and has been increasingly reported for neuroendocrine tumors located at the body and tail of the pancreas.
  • We report a case of successful enucleation of a nonfunctioning neuroendocrine tumor located at the head of the pancreas, in a patient with multiple endocrine neoplasia type I.
  • METHODS: A 5-cm nonfunctioning neuroendocrine tumor at the pancreatic head was identified by computerized tomography scan.
  • Laparoscopic ultrasound did not reveal additional tumors on any other part of the pancreas.
  • RESULTS: Enucleation was successfully performed for this solitary tumor because of its favorable position.
  • Histology revealed an islet cell tumor.
  • CONCLUSION: Laparoscopic enucleation of neuroendocrine tumor at the pancreatic head is safe and feasible for select patients.

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jun;231(6):909-18 [10816635.001]
  • [Cites] Surgery. 2000 Sep;128(3):386-91 [10965308.001]
  • [Cites] Surgery. 2001 Dec;130(6):1086-91 [11742343.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1057-65 [12016486.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Eur J Endocrinol. 2003 Jan;148(1):39-43 [12534356.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):297-302 [14712388.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):488-93; discussion 493-4 [7725733.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] World J Surg. 2002 Oct;26(10):1297-300 [12205557.001]
  • (PMID = 16882434.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3016133
  •  go-up   go-down


90. Yüksel M, Eziddin S, Wardelmann E, Biersack HJ: 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy. Rev Esp Med Nucl; 2006 Sep;25(5):316-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with suspicion of a neuroendocrine tumor of the pancreas underwent a somatostatin receptor scintigraphy using 111In-Pentetreotide.
  • Normal thyroid tissue and thyroid disorders, such as cancers, Hashimoto's thyroiditis, and adenomas often show increased uptake of 111In-pentetreotide resulting in a possible false positive interpretation in patients with neuroendocrine tumor.
  • Adding a 48h planar image might contribute to the differential diagnosis between benign or malignant lesions, as in the present case where the uptake decreased in an adenoma after 48 hours.
  • [MeSH-major] Adenoma / radionuclide imaging. Indium Radioisotopes / pharmacokinetics. Neuroendocrine Tumors / radionuclide imaging. Neuroendocrine Tumors / secondary. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics. Somatostatin / analogs & derivatives. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Chromogranin A / analysis. Diagnosis, Differential. False Positive Reactions. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / radionuclide imaging. Receptors, Somatostatin / metabolism. Serotonin / analysis. Thyroglobulin / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173778.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Indium Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 333DO1RDJY / Serotonin; 51110-01-1 / Somatostatin; 9010-34-8 / Thyroglobulin; G083B71P98 / pentetreotide
  •  go-up   go-down


91. Strom T, Kleinschmidt-Demasters BK, Donson A, Foreman NK, Lillehei KO: Rare nerve lesions of non-nerve sheath origin: a 17-year retrospective series. Arch Pathol Lab Med; 2009 Sep;133(9):1391-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, once a peripheral nerve mass is determined not to be a nerve sheath neoplasm, differential diagnostic considerations drop off sharply.
  • After elimination of common lesions (mostly nerve sheath tumors), 37 cases (8%) remained, almost all of which were of non-nerve sheath origin: for example, hemangioma, metastatic neuroendocrine pancreatic carcinoma, meningiomas invading nerve fascicles, and primary extrarenal rhabdoid tumor and Ewing sarcoma of nerve.
  • The gene expression pattern of an undifferentiated sarcoma, presenting as ropelike nerve enlargement, clustered with malignant peripheral nerve sheath neoplasms but not other sarcomas or neuroepithelial tumors.
  • CONCLUSIONS: Diverse benign and malignant conditions can affect peripheral nerve.
  • [MeSH-major] Hemangioma / pathology. Meningioma / pathology. Pancreatic Neoplasms / pathology. Peripheral Nervous System Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722745.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


92. Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC: Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer; 2008 Mar;15(1):243-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
  • Current classifications of human gastroenteropancreatic neuroendocrine tumors (NETs) are inconsistent and based upon histopathologic but not molecular features.
  • We sought to compare a molecular classification with the World Health Organization (WHO) histologic classification, identify genes that may be important for tumor progression, and determine whether gastrointestinal NETs (GI-NETs) differ in their molecular profile from pancreatic NETs (PNETs).
  • Hierarchical clustering of 19 PNETs revealed a 'benign' and 'malignant' cluster that corresponded well with the WHO categories of well-differentiated endocrine tumor (WDET) and well-differentiated endocrine carcinoma (WDEC) respectively.
  • Gene expression profiles reflect the current WHO classification and can distinguish benign from malignant PNETs and also PNETs from GI-NETs.
  • This suggests that molecular profiling may enhance tumor classification schemes.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310291.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; None / None / / P30 DK040561-12; United States / NIDDK NIH HHS / DK / P30 DK040561-12
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


93. Ardeleanu C, Dănăilă L, Arsene D: Paraganglioma of the cerebellopontine angle. Case presentation and pathological considerations. Rom J Morphol Embryol; 2005;46(3):171-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraganglioma of the cerebellopontine angle. Case presentation and pathological considerations.
  • Paragangliomas (glomus tumors) arise from the extra-adrenal neuroendocrine system.
  • They are benign but locally aggressive tumors, causing bone destruction and compression related symptoms.
  • We present a case of paraganglioma of the cerebellopontine angle.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Paraganglioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444300.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


94. Pasieka JL: Carcinoid tumors. Surg Clin North Am; 2009 Oct;89(5):1123-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid tumors.
  • Carcinoid tumors, which arise from the enterochromaffin cells of the gastrointestinal tract, encompass a diverse group of neoplasms.
  • Once thought to be "carcinoma-like," these neoplasms exhibit a biologic behavior that varies from an indolent, benign course to an aggressive, rapidly progressive, and deadly disease.
  • Today the term carcinoid is reserved for neuroendocrine tumors arising from the small bowel or neuroendocrine tumors that can cause carcinoid syndrome.
  • For the general surgeon there are several "carcinoid" tumors that he or she must be familiar with because many of these lesions are encountered during emergency laparotomies or incidentally discovered during investigation for vague abdominal pain.
  • This review focuses on the gastrointestinal neuroendocrine tumors that general surgeons are likely to encounter during their career.
  • [MeSH-major] Carcinoid Tumor / surgery. Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836488.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


95. Gil da Costa RM, Rema A, Pires MA, Gärtner F: Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein. Vet Dermatol; 2010 Apr;21(2):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two canine Merkel cell tumours: immunoexpression of c-KIT, E-cadherin, beta-catenin and S100 protein.
  • Canine Merkel cell tumours are rare neuroendocrine neoplasms that show a relatively benign biological behaviour when compared with their human counterparts.
  • This report describes the histopathological and immunohistochemical features of two such tumours.
  • The tumours' immunoreactivity profile was studied with respect to different cellular molecules including chromogranin A (CGA), neurone-specific enolase (NSE), S100 protein, c-KIT, the cytokeratins (CKs) detected by pancytokeratin (AE1/AE3) antibodies (i.e. high molecular weight CKs 1, 2, 3, 4, 5, 6, 10, 14, 15 and 16, and low molecular weight CKs 7, 8 and 19) and three markers proposed to correlate with increased malignancy in human tumours: E-cadherin, beta-catenin and p63 protein.
  • In both lesions, tumour cells were positive for cytokeratins, CGA, NSE, S100 and c-KIT.
  • These results suggest that the generally benign behaviour of canine Merkel cell tumours, when compared with their human counterparts, may be partly explained by the conservation of important intercellular adhesion molecules such as E-cadherin and beta-catenin.
  • Additionally, expression of S100 but not of the p63 protein suggests that these canine tumours present a trend towards neural, rather than basal, epithelial differentiation and do not readily compare with human Merkel cell tumours.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Merkel Cell / metabolism. Dog Diseases / diagnosis. Proto-Oncogene Proteins c-kit / metabolism. S100 Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Dogs. Female. Gene Expression Regulation, Neoplastic / physiology. Male

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706008.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / S100 Proteins; 0 / beta Catenin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


96. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumours--analysis of own material--a nine--year retrospective study.
  • BACKGROUND/AIMS: Neuroendocrine tumours are fairly rare neoplasms that require different treatments and have various prognoses.
  • The aim of this study was to present the author's observations of the histological tumor types, occurrence and its surgical treatment.
  • METHODOLOGY: Thirty-five cases of neuroendocrine tumours were studied retrospectively in a 9-year period.
  • Ultrasonography, scintigraphy, computed tomography or magnetic resonance imaging of abdominal cavity, pelvis, thorax or neck--depend on the tumor localization--were done in every individual.
  • All cases were subjected to surgical procedure with an aim to resect the tumour completely.
  • RESULTS: In the present study were observed 6 cases of carcinoids localized in ileum, cecum and sigmoid colon, 1 case of gastrinoma in pancreatic head localization, 1 case of insulinoma localized in pancreatic tail, 1 case of vipoma localised in pancreatic head, 2 cases of nesidioblastoma and 1 case of microcystic adenoma with neuroendocrine differentiation in pancreatic tail localization and 1 case of nonspecific apudoma observed in ileum.
  • There were 6 cases of neuroendocrine tumours localized in pancreas.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • CONCLUSIONS: Neuroendocrine tumours occur very rare.
  • The clinical manifestations of some neuroendocrine tumours are not specific, so it causes a lot of difficulties in early diagnosis and treatment.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


97. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E: Pulmonary carcinoid tumours: indolent but not benign. Oncology; 2007;73(3-4):162-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary carcinoid tumours: indolent but not benign.
  • BACKGROUND: The aim of this retrospective study was to analyse the malignant behaviour of low-grade pulmonary neuroendocrine tumours (NETs) treated at our institution.
  • RESULTS: At diagnosis, there were 37 metastatic and 11 non-metastatic patients.
  • CONCLUSION: Cell type is the strongest determinant of prognosis, and the degree of malignancy increases from TCs to ACs.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418008.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


98. Neto MB, Machado MC, Mesquita F, de Castro Musolino NR, Toscanini AC, Ochman G, Cescato VA, Marino R Jr, Teixeira MJ: Thymus hyperplasia after resolution of hypercortisolism in ACTH-dependent Cushing's syndrome: the importance of thymic vein catheterization. Eur J Endocrinol; 2006 Jun;154(6):807-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case where the catheterization of the thymic vein was essential for the differential diagnosis of a thymic enlargement in an adrenalectomized patient with ACTH-dependent Cushing's syndrome.
  • She underwent a transsphenoidal surgery with no tumor visualization and no remission of the syndrome.
  • She did not undergo thoracotomy and a follow-up was established.
  • During the evolution, there was a spontaneous regression of the thymic lesion 38 months after the diagnosis.
  • The ACTH gradient during the catheterization of thymic vein was essential for the differential diagnosis of the thymic enlargement tumor after hypercortisolism resolution in ACTH-dependent Cushing's syndrome, especially in this case, where the ACTH source was occult, thus avoiding an invasive surgical procedure for a benign entity with spontaneous resolution.